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ABSTRACT
Background: Human Papillomavirus (HPV) is the most common sexually transmitted
disease in the world. It is associated with significant morbidity and mortality in both
sexes, accounting for approximately 5% of all cancers worldwide. Receiving the HPV
vaccine can substantially reduce the risk of HPV infection and subsequent disease. At
this time the majority of Americans reach adulthood without being vaccinated.
Increasing HPV vaccination among young adults requires empirical assessment and
understanding of HPV-related beliefs and behaviors among this population. To
achieve this goal, three studies were conducted.
Study 1: This study examined demographic and psychosocial correlates of HPV
vaccination among 834 young adults. HPV vaccination rates in this sample were
73.7% for women and 26.1% for men. Gender comparisons indicated women were
more likely to have heard of HPV, received the HPV vaccine, and had higher HPVrelated knowledge. Health-care providers and mothers were common sources of
vaccine recommendation among men and women. Those who identified as white
and/or Hispanic and participants with health insurance were most likely to have
received the vaccine. Other predictors of vaccination included higher HPV-related
knowledge and perceived responsibility for HPV prevention. These findings
underscore several important demographic and psychosocial factors associated with
HPV vaccination.
Study 2: This study developed and validated measures of the TTM constructs Stage of
Change, Decisional Balance, and Self-Efficacy in young adult men (N = 329). The
stage distribution was: Precontemplation 54.1%, Contemplation 14.6%, Preparation

5.2%, and Action/Maintenance 26.1%. Principal Components Analysis (PCA)
performed on a split half sample revealed a 2-factor solution for the Decisional
Balance scale, representing both Pros (α = 0.78) and Cons (α = 0.83). For the SelfEfficacy scale, PCA revealed a single-factor solution (α = 0.83). Confirmatory Factor
Analysis (CFA) confirmed that the two-factor uncorrelated model for Decisional
Balance, χ² (35) = 82.6, p < .001, CFI = .92, GFI = .92, AASR = .06, and a single
factor model for Self-Efficacy, χ² (14) = 43.4, p < .001, CFI = .93, GFI = .92, AASR =
.04. Follow-up ANOVAs supported the theoretically predicted relationships between
Stage of Change, Pros, and Self-Efficacy. Overall, these results support the validity of
these TTM measures for HPV vaccination among young adult men and provide the
foundation for an intervention to promote vaccine acquisition.
Study 3: This study examined gender invariance for measures of Decisional Balance
and Self-Efficacy for HPV vaccination using data collected from 329 men and 505
women. The original measures were developed in Study 2 and in past research.
Structural equation modeling was used to test for factorial invariance. Pattern Identity
Invariance was a good fit for the Decisional Balance measure. The highest level of
invariance, Strong Factorial, was a very good fit for Self-Efficacy. Evidence of Pattern
Identity and Strong Factorial invariance for Decisional Balance and Self-Efficacy,
respectively, indicates that measures of the latent constructs Decisional Balance and
Self-Efficacy are the same across male and female subgroups. These measures will
yield meaningful comparisons of men and women in future research and clinical
applications.

ACKNOWLEDGMENTS
I would like to acknowledge and thank my major professor, Dr. James Prochaska
for the guidance and support he has provided me throughout my academic and
scientific pursuits. His help has been instrumental in the conceptualization and
completion of this dissertation. I would also like to thank my dissertation committee,
Dr. Joseph Rossi, Dr. Judith Swift, and Dr. Jasmine Mena for their expert guidance
and thoughtful advice. In addition, Dr. Andrea Paiva deserves special mention for her
support and statistical expertise that she was willing to share at a moment's notice. I
would also like to recognize Dr. Mark Wood, my master's thesis advisor, who was
integral to my research training and progress towards this doctoral work. Thank you to
my parent's Mark and Laura Fernandez, who were always there to support me, and my
friends who made graduate school such a wonderful and fun experience.

iv

TABLE OF CONTENTS

ABSTRACT .................................................................................................................. ii
ACKNOWLEDGMENTS .......................................................................................... iv
TABLE OF CONTENTS............................................................................................. v
LIST OF TABLES ...................................................................................................... vi
LIST OF FIGURES ................................................................................................... vii
CHAPTER 1 ................................................................................................................. 1
INTRODUCTION ................................................................................................... 1
CHAPTER 2 ............................................................................................................... 17
METHODOLOGY................................................................................................. 17
CHAPTER 3 ............................................................................................................... 32
RESULTS .............................................................................................................. 32
CHAPTER 4 ............................................................................................................... 43
DISCUSSION ........................................................................................................ 43
CHAPTER 5 ............................................................................................................... 58
CONCLUSION ...................................................................................................... 58
Appendix A. ................................................................................................................ 84
BIBLIOGRAPHY .................................................................................................... 117

v

LIST OF TABLES

TABLE

PAGE

Table 1. Demographics of Male and Female Sample. ................................................ 61
Table 2. Original and Final Items for Male and Female Decisional
Balance Measure ......................................................................................................... 62
Table 3. Original and Final Items for Male and Female Self-Efficacy Measures ...... 63
Table 4. Knowledge Items and Accuracy of Responses ............................................ 64
Table 5 Results of Principal Components Analysis for Knowledge Scale ................. 65
Table 6. Fit Indices for Knowledge and Perceived Responsibility Models ................ 66
Table 7. Means of Perceived Responsibility Items among Men and Women ............ 67
Table 8. Results of Principal Components Analysis for Perceived Responsibility
Scale ............................................................................................................................ 68
Table 9. Magnitude of Effect Sizes for Predictors of HPV vaccination ..................... 69
Table 10. Results of Principal Components Analysis for Decisional Balance Scale.. 70
Table 11. Results of Principal Components Analysis for Self-Efficacy Scale ........... 71
Table 12. Fit Indices for Decisional Balance and Self-Efficacy Confirmatory
Models ......................................................................................................................... 72
Table 13. Means and Standard Deviations of Raw Scores for Decisional Balance and
Self-Efficacy across the Stages of Change.................................................................. 73
Table 14. Goodness of Fit Statistics for Invariance Models ....................................... 74

vi

LIST OF FIGURES

FIGURE

PAGE

Figure 1. Stages of Change for HPV Vaccination. ..................................................... 75
Figure 2. Knowledge Scale Structural Model. ............................................................ 76
Figure 3. Perceived Responsibility Structural Model ................................................. 77
Figure 4. Male Decisional Balance Confirmatory Model ........................................... 78
Figure 5. Male Self-Efficacy Confirmatory Model..................................................... 79
Figure 6. Stage of Change by Decisional Balance ANOVA Results .......................... 80
Figure 7. Stage of Change by Self-Efficacy ANOVA Results ................................... 81
Figure 8. Decisional Balance CFA Model with Standardized Parameter Estimates for
the Male and Female Sample ...................................................................................... 82
Figure 9. Self-Efficacy CFA Model with Standardized Parameter Estimates for the
Male and Female Sample ............................................................................................ 83

vii

CHAPTER 1

INTRODUCTION

Lifetime risk of HPV infection exceeds 50% for men and women (Centers for
Disease Control and Prevention, 2009). With regards to men, a literature review of 40
studies of HPV prevalence (types, 6, 11, 16, and 18) indicated prevalence rates that
ranged from 1.3%-72.9% (Dunne, Nielson, Stone, Markowitz, & Giuliano, 2006). In
general, studies that sampled multiple anatomical sites and specimens found higher
incidences of HPV infection (Dunne et al., 2006; Nielson et al., 2007). In one such
comprehensive study, overall HPV prevalence was 65.4% among 463 men ages 18 to
40 (Nielson et al., 2007) indicating that HPV prevalence may be even higher than
research typically reports. Prevalence estimates of HPV infection among women also
vary, and rates are comparable to those reported among men. In a longitudinal study of
women who were negative for HPV at a baseline, 60% of the women contracted HPV
at some point over a five year follow-up period (Baseman & Koutsky, 2005). In a
large national sample of women (N = 4,150) ages 14 - 59, the rate of current HPV
infection was 42.5% overall (Hariri et al., 2011).
In addition to anogenital HPV infection, oral HPV infection is a growing concern
internationally among both men and women (Chaturvedi et al., 2011; Ramqvist &
Dalianis, 2010). Approximately, 6.9% of men and women in the United States had an
oral HPV infection in a recent national study (Gillison et al., 2012).
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HPV-Related Health Problems
HPV infection can lead to a myriad of health problems including anogential
cancers, oropharyngeal cancers, and anogenital warts. Although most cases of HPV
clear on their own, HPV infection is implicated in approximately 99% of all cases of
cervical cancer (Wang, 2007), 90-93% of anal cancers, 12-63% of oropharyngeal
cancers, and 36-40% of penile cancers (Chaturvedi, 2010). Prior to HPV vaccination
licensure for the years 1998 to 2003, 25,000 cases of HPV-associated cancers occurred
annually in 38 states and the District of Columbia (Centers for Disease Control and
Prevention, 2008a). While cervical cancers were the most common (10,800 annually),
almost 7,400 potentially HPV-associated head and neck cancers occurred per year.
The vast majority of these (5,700) were among men. Additionally, there were over
3,000 HPV-associated anal cancers per year (1,900 in women, and 1,100 in men),
2,300 incidences of vulvar cancer, 800 incidences of penile cancer, and 600 incidences
of vaginal cancer (Hernandez et al., 2008; Joseph et al., 2008; Ryerson et al., 2008;
Saraiya et al., 2008; Watson et al., 2008).
Women are disproportionately affected by HPV-related cancers and as a result
prevention efforts have predominately targeted females only. Due to these targeted
efforts rates of cervical cancer have decreased in the United States, while rates of other
HPV-related cancers have increased (Chaturvedi, 2010). Oral cancer, the second most
common HPV-associated cancer, is on the rise, especially among males (Ryerson et
al., 2008). In a large population based study, the overall prevalence of oral HPV
infection was significantly higher for men (10.1%) than women (3.6%) even after
controlling for sexual behavior (Gillison et al., 2012). Anal cancer diagnosis has
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increased several fold since 1973 (Maggard, Beanes, & Ko, 2003). Anal cancer occurs
in both genders, but survival rates following diagnosis are lower for men at all stages
of the disease (Joseph et al., 2008).
Alarmingly, among men who have sex with men rates of anal cancer are higher
than rates of cervical cancer among women (Chin-Hong et al., 2005; Goedert et al.,
1998; Jemal et al., 2003). Although anal HPV infection is not uncommon among
heterosexual men (Nyitray et al., 2010) it has been called “nearly universal” among
gay and bisexual men (Vajdic et al., 2009) who are 17 times more likely to develop
anal cancer. Individuals with weak immune systems, such as those carrying the human
immunodeficiency virus (HIV) are also at higher risk for developing HPV-related
cancers and are also more likely to get severe cases of genital warts that are hard to
treat (Centers for Disease Control and Prevention, 2010). These increasing rates of
anal and oropharyngeal cancers, particularly among men, warrant additional
prevention efforts.
Race, ethnicity, education, and socio-economic status are also related to HPV
infection, morbidity, and mortality. African- American women are at greater risk for
HPV infection (Hariri et al., 2011), incidence of cervical cancer (Schairer, Brinton,
Devesa, Ziegler, & Fraumeni, 1991), and morbidity resulting from cervical cancer
(Ries et al., 2006). Hipanic/Latina women are also more likely to be diagnosed with
cervical cancer, and Hispanic men suffer from a disproportionate number of HPVrelated cancers (Colón-López, Ortiz, & Palefsky, 2010; Hernandez et al., 2008). Rates
of HPV infection and related cancers may be lower among Asian/Pacific Islanders
(Akogbe et al., 2012; Hernandez et al., 2008). Lower education and higher poverty are
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also associated with incidence of HPV-related cancer (Benard et al., 2008; Hernandez
et al., 2008).
While the development of anogenital and oropharyngeal cancers are the most
serious HPV-related risks, HPV diagnosis and genital warts have a substantial
psychosocial impact on the individual and society (Daley et al., 2010; Jeynes, Chung,
& Challenor, 2009). The Centers for Disease Control and Prevention (CDC) indicates
that about 1% of males and females in the U.S. have genital warts at some time in their
lives (Centers for Disease Control and Prevention, 2008b). However, the National
Disease and Therapeutic Index estimates are much higher. During their 1999-2004
survey years 5.6% (95% CI: 4.9-6.4) of sexually active 18-59 year olds self-reported a
history of a genital wart diagnosis (Dinh, Sternberg, Dunne, & Markowitz, 2008).

HPV Vaccination
In June 2006, a quadrivalent HPV (Gardisil) vaccine was licensed for use in the
United States among females ages 9 – 26 to prevent anogenital cancers, precancerous
lesions, and genital warts (U.S. Food and Drug Administration, 2006). Gardisil is a
quadrivalent vaccine that provides protection against the four strains of HPV, namely
types 6, 11, 16, and 18. Types 6 and 11 are “low-risk” strains that can lead to genital
warts, while types 16 and 18 are “high-risk” strains that can lead to various cancers
and precancerous lesions (Centers for Disease Control and Prevention, 2009). A
second bivalent vaccine (Cervarix) was approved for use among women in 2009 and
protects against high-risk HPV types 16 and 18 (U.S. Food and Drug Administration,
2009b). In October, 2009 the US Food and Drug Administration approved the
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quadrivalent vaccine to prevent genital warts among males ages 9 -26 years old (U.S.
Food and Drug Administration, 2009a), and in 2010 it was approved to prevent anal
cancers and precancerous lesions among males and females ages 9-26 (U.S. Food and
Drug Administration, 2010).
Following approval from the FDA, the Advisory Committee on Immunization
Practices (ACIP) conducted an investigation and recommended routine use of the
quadrivalent HPV vaccine for females in 2007 and for males in 2011 (Centers for
Disease Control and Prevention, 2007; Centers for Disease Control and Prevention,
2011b). The recommended schedule is a 3-dose series with the second and third doses
administered two and six months after the first dose. The recommended age for
vaccination of males and females is 11-12 years, but can be administered as young as
9 years. “Catch-up” vaccination is recommended for females aged 13-26 and males
ages 13-21 years who have not been previously vaccinated. Men as old as 26 years
may be vaccinated but they fall outside the age range for “routine” vaccination.
According to the CDC, the cost of the vaccine in 2010 is $125 per dose ($375 for
series) making it the most expensive vaccine in the U.S. immunization schedule. It is
the only vaccine that prevents a sexually-transmitted disease (Rodewald & Orenstein,
2009) and the only vaccine that prevents against any form of cancer.
Vaccine Controversy. The HPV vaccine has been controversial since its debut
due to doubts about its efficacy and safety as well as religious and moral objections
related to its association with sexual activity (Benítez-Bribiesca, 2009). Many of these
safety and efficacy concerns are unsubstantiated but continue to persevere in the
general population and popular press. In particular, the appropriateness and cost-
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effectiveness of male-vaccination is an area of ongoing debate and controversy
(Stupiansky, Alexander, & Zimet, 2012). Those who support the universal
recommendation for the HPV vaccine in men point out that the female-only
recommendation (a) does not protect men who have sex with men, (b) that genderneutral vaccination is the quickest way to produce “herd-immunity,” (c) that both
genders transmit HPV and thus a universal vaccine is more equitable from a public
health perspective, (d) that men suffer from genital warts and HPV-related cancers,
and (e) that a universal vaccination is generally more effective and less confusing to
the public (Rosenthal & Zimet, 2010). The majority of practicing physicians supported
the gender-neutral vaccine recommendation; 94% either somewhat or strongly agree
that men should be vaccinated (Weiss, Zimet, Rosenthal, Brenneman, & Klein, 2010).
Those who oppose the HPV vaccine for males argue that male vaccination is not costeffective if female vaccination rates are high, and that the need to prevent HPV
infection in high-risk subgroups (e.g. men who have sex with men) does not warrant
vaccination of all men (Peres, 2010).
Due to these ongoing debates and uncertainty regarding the cost-effectiveness of
male vaccination, the ACIP provided a “permissive” recommendation for male HPV
vaccination in 2009 allowing for the administration of the HPV vaccine among males
ages 9-26 but not making it part of their routine vaccination schedule (Peres, 2010).
The full-recommendation was made two years later in 2011, a full four years after the
female vaccination received the same recommendation (Centers for Disease Control
and Prevention, 2011b). The ACIP made the full-recommendation on the basis of
vaccine safety data, the estimated impact of HPV-related disease and cancer on men
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and women, cost-effectiveness analysis, and other programmatic considerations. Costeffectiveness studies suggest that the male vaccination is cost-effective when female
vaccine coverage is low and the full range of HPV-related health-outcomes and
associated-diseases are considered (Centers for Disease Control and Prevention,
2011b). Private insurance coverage of the vaccine(s) varies, however the “routine”
recommendation means that most will cover the vaccine for males and females.
Vaccination is covered by managed care organizations, the vaccine for children
program, and those without private health insurance may by reimbursed through
Merck-funded assistance programs (Haupt & Sylvester, 2010)
Gender and HPV Vaccination. Due to its very recent licensure and approval,
limited data is available on HPV uptake among men but estimates from 2011, indicate
that as few as 2.8% of adult men between the ages of 19-21 received ≥ 1 dose of the
vaccine, relative to 43.1% of young adult women in the same age range (Centers for
Disease Control and Prevention, 2013). This is an increase from 2010 when less than
1% of adult men, and 28.2% of adult women had received any doses of the vaccine.
Among adolescent males, 8.3% received ≥ 1 dose of the vaccine in 2011, while over
half (53.0%) of adolescent girls were vaccinated (Centers for Disease Control and
Prevention, 2012). Collectively, these data reveal that in recent years approximately
half of females and the vast majority of males in the US reach adulthood without
receiving the HPV vaccine. Unfortunately, vaccination rates also remain low when
men and women turn 18 and can make their own medical decisions.
Given the gender difference in vaccine uptake and earlier vaccine licensure, it is
not surprising that women have higher awareness of HPV and the HPV vaccine. In
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research recruiting nationally representative samples, 79% of women were aware of
the availability of the HPV vaccine (Jain et al., 2009), relative to 73% of gay and
bisexual men (Reiter, Brewer, McRee, Gilbert, & Smith, 2010), and 63% of
heterosexual adult men (Reiter, Brewer, & Smith, 2010). Research that directly
compares men and women’s awareness of HPV and acceptability of the vaccine is still
emerging but reveals discrepancies between men and women, with women having
higher rates of knowledge and intentions to be vaccinated. Among students (N = 575)
at three colleges, males were significantly less likely to have heard of HPV, scored
lower in HPV knowledge, were less likely to perceive HPV health outcomes as severe,
less likely to perceive benefits of the vaccinate, reported fewer cues for vaccine
acceptance, and perceived more barriers to vaccination compared to females (Bynum,
Brandt, Friedman, Annang, & Tanner, 2011). In a study of young adults at two
universities, 94% of women had heard of HPV as compared to 62% of men. Women
also had higher overall knowledge scores, while men had higher perceived shame
related to HPV vaccination diagnosis (Gerend & Magloire, 2008). These gender
differences are not limited to American adults. Awareness and knowledge of HPV is
higher among women in Holland (Lenselink et al., 2008), Australia (Pitts et al., 2010),
and Portugal as well (Medeiros & Ramada, 2010). These findings underscore that
education is an initial hurdle in terms of increasing male vaccination; Without
awareness of HPV and the availability of the vaccine, interest in vaccination among
men will remain low.
Race/Ethnicity and HPV Vaccination. Intention to vaccinate varies across
racial and ethnic subgroups. Results of research generally indicate that individuals
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who identify as white have higher rates of vaccine uptake and intention to receive the
HPV vaccine, and some research has found higher rates of vaccination among
Hispanic women as well. A study of women receiving Medicaid in Florida revealed
Hispanic women had the highest rates of vaccinate initiation followed by white nonHispanic women. Black women had the lowest rates of vaccine initiation and were
half as likely as their white counterparts to complete the 3-shot vaccine series (Cook et
al., 2010). A study of adolescent girls in Pittsburgh reported similar racial disparities,
indicating that even after controlling for public assistance; black females were
approximately 35% less likely than white females to have any dose of the HPV
vaccine (Keenan, Hipwell, & Stepp, 2012). Among 1,019 women ages 18-24 years
old, non-Hispanic white women were most likely to report HPV vaccination and
awareness, followed by non-Hispanic black women, and Hispanic women (Ford,
2011).
Among men there is initial evidence that Hispanic men are more likely to intend
to receive the HPV vaccine, relative to non-Hispanic white men, and non-Hispanic
black men (Daley et al., 2011). These findings underscore the importance of HPV
vaccine promotion efforts among diverse populations.
HPV Vaccination and College Students. College students are an important
population to target with regards to HPV prevention and HPV vaccination promotion.
College students tend to be the appropriate age for adult HPV vaccination and are at
high risk for contracting HPV (Partridge et al., 2007). Research indicates students are
more willing to be vaccinated than the general public. A literature review of male
attitudes regarding the HPV vaccine indicates that 74% - 78% of college men reported
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they were willing to get the HPV vaccine, compared to 33% of men in a community
sample (Liddon, Hood, Wynn, & Markowitz, 2010). College attending women are
also more likely to indicate intentions to receive the HPV vaccine relative to their non
college-attending peers (Manhart et al., 2011). Despite increased willingness to
receive the HPV vaccine, qualitative research suggests that there are many
misperceptions about HPV and underestimation of risk among college students (Allen,
Fantasia, Fontenot, Flaherty, & Santana, 2009). In a recent study, men recognized that
HPV was a sexually transmitted infection that was more common among individuals
with numerous sexual partners. However, it was still perceived as a “women’s
disease.” Awareness of HPV-related cancers in men was low and many
misunderstandings about the actual effects of HPV were apparent. Men were also
apprehensive about the idea of being vaccinated, vocalizing doubts about vaccine
safety, cost, and accessibility. In general men emphasized that education is necessary
before prevention efforts will be successful among adult men (Allen et al., 2009).
College women also misperceive the prevalence and risks associated with HPV
infection. Licht and colleagues (2010) found that college women underestimate the
risk of acquiring and transmitting HPV, and women with higher knowledge of specific
HPV health risks were more likely to have received the HPV vaccine (Licht et al.,
2010).

HPV Vaccine Promotion
Increasing knowledge about HPV and awareness of the availability of the HPV
vaccine are important steps for prevention of HPV. Examining HPV-related
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knowledge is consistent with the health belief model and is included in the
'Consciousness Raising' process within the Transtheoretical Model of Change (J. O.
Prochaska, Velicer, DiClemente, & Fava, 1988; J. O. Prochaska & DiClemente, 1983;
von Wagner, Steptoe, Wolf, & Wardle, 2009). Health-literacy is considered an
important factor in decision-making and miscommunication of health information can
have deleterious effects (von Wagner et al., 2009). Research indicates that men and
women have critical knowledge deficits with regards to HPV viral transmission,
prevention, screening, and treatment (Allen et al., 2009; Licht et al., 2010; Sandfort &
Pleasant, 2009; Wong & Sam, 2010). Brief educational interventions have been
effective at correcting such knowledge deficits, increasing understanding of HPV, and
increasing positive attitudes towards HPV vaccination (Gottvall, Tydén, Höglund, &
Larsson, 2010; Lambert, 2001; Reiter, Stubbs, Panozzo, Whitesell, & Brewer, 2011).
While health-literacy is an important factor in many areas of health-related
decision making, knowledge-based interventions are not necessarily sufficient for
increasing intention to vaccinate. For example, among parents, an HPV vaccine
information sheet increased post-intervention knowledge but not intentions to
vaccinate their child relative to a control group (Dempsey, Zimet, Davis, & Koutsky,
2006). An experimental study that provided men with education about the health
benefits of HPV vaccination found that educating them about benefits to the partner
(e.g. preventing cervical cancer) did not increase intentions to receive the vaccine
(Gerend & Barley, 2009). While knowledge and awareness are essential for young
adults to make informed decisions about HPV prevention, information alone does not
appear to be a sufficient to increase vaccination rates. Similar conclusions have been
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drawn in other areas of health behavior change (Baranowski, Cullen, Nicklas,
Thompson, & Baranowski, 2003).

Psychosocial Predictors of Vaccination
There are a number of behavioral and psychosocial predictors of HPV
acceptability and uptake include being sexually active, having a higher number of
lifetime sexual partners, having higher perceived efficacy of vaccine, having higher
perceived health benefits of the vaccination, having a higher perceived susceptibility
to HPV physician recommendation, and anticipated regret if one were to forgo
vaccination and later contract HPV (Anhang Price, Tiro, Saraiya, Meissner, & Breen,
2011; Brewer & Fazekas, 2007; Daley et al., 2011; Dempsey, Butchart, Singer, Clark,
& Davis, 2011; Keenan et al., 2012; Krawczyk et al., 2012; Liau, Stupiansky,
Rosenthal, & Zimet, 2012; Lu et al., 2011; Reiter, Brewer, & Smith, 2010; Reiter,
Brewer, McRee et al., 2010). HPV vaccine cost and access are also important
predictors of vaccine intentions. Increasing cost of the HPV vaccine is inversely
related to intention to vaccinate among men and women (Liau et al., 2012), as is being
uninsured (Anhang Price et al., 2011; Patel et al., 2012). Less than half of adult men
in one study reported they had somewhere they could get the vaccine (Daley et al.,
2011) which underscores the importance of increasing men’s awareness of vaccine
providers and outlets. Future interventions should aim to apply to intervene on
modifiable and empirically-based predictors of vaccination, not just aim to increase
knowledge and awareness of HPV and the vaccine.
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Interventions that use psychological theory or target behavioral factors in an
effort to increase HPV vaccination are not well-represented in the literature. However,
several novel intervention strategies have been successfully implemented. One study
used text messaging to promote vaccine series completion. This intervention
effectively increased completion of the second and third dose of the HPV vaccine
using text reminders; however, participants self-selected in to the text-messaging
program and may have been more intrinsically motivated to complete the series
(Kharbanda et al., 2011). A four-arm randomized study examined the efficacy of
culture-centric narrative interventions. Results indicated college women were almost
twice as likely to report HPV vaccination at a 2-month follow-up after watching a
video that combined peer- and expert-based narratives on HPV vaccination. Mediation
analyses indicated that increases in self-efficacy (psychological and logistical)
mediated increases in HPV vaccination (Hopfer, 2012). However, watching the peerbased narrative alone did not increase HPV vaccination, and watching the expertbased narrative alone actually decreased HPV vaccination rates relative to the control
group. These results underscore the importance of message source and self-efficacy in
promoting vaccination and also the complexity of the vaccine-related decision-making
process.

The Transtheoretical Model of Change
Clearly there is a need for an intervention among young adults, and men in
particular, to increase HPV-related knowledge, acceptability, and motivation to
receive the HPV vaccine series. However, before such intervention can occur, reliable
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and valid measures must be developed to assess knowledge, attitudes, and motivation
as they relate to HPV and the HPV-vaccination. Measures that are organized around a
systematic behavior change framework would be particularly useful for future
intervention development and tailoring. One such framework is the Transtheoretical
Model of Behavior Change (TTM). The TTM is an integrative model of behavior
change that uses the constructs of Stages of Change, Decisional Balance, Selfefficacy, and Processes of Change to understand and predict how people make
behavioral health changes (C. C. DiClemente, Prochaska, & Gibertini, 1985; C. C.
DiClemente et al., 1991; J. O. Prochaska & DiClemente, 1983; Velicer, DiClemente,
Prochaska, & Brandenburg, 1985). Stage of Change is the central organizing construct
of the TTM. It represents a temporal/developmental dimension as evidenced by 5
stages: Precontemplation (PC), Contemplation (C), and Preparation (PR), Action (A),
and Maintenance (M). Traditionally, Precontemplators are those who are not intending
to make a change (i.e. get vaccinated) in the next six months. Contemplators are
intending to change in the next six months. People in the Preparation stage are
planning to change in the next 30 days (and have made a previous attempt to
improve). People in the Action and Maintenance stages have reached some behavioral
criterion (such as successful vaccination), with those in Action having reached
criterion within the last six months.
The Decisional Balance construct provides a measure of an individual’s rating of
the relative importance of the pros versus the cons of changing a specific behavior
(Velicer et al., 1985). Research indicates that the pros are more salient in the earlier
stages and the cons are more important to intervene upon in the later stages (Hall &
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Rossi, 2008). A crossover in which pros begin to outweigh cons typically occurs in
during the preparation stage, and is believed to be necessary for behavior change to
occur. Self-efficacy theory originally proposed by Bandura (Bandura, 1977; Bandura,
1982) was adapted for use with the TTM. Situational self-efficacy embodies the level
of confidence an individual has to engage in a new behavior or to maintain a behavior
in a variety of challenging situations (Velicer, DiClemente, Rossi, & Prochaska,
1990). Self-efficacy, is expected to increase as one progresses through the stages (J. S.
Rossi & Redding, 2001).

The Current Study
This study aims to examine motivation and decision-making related to HPV
vaccination among male and female college students using the TTM as an organizing
framework. The proposed research represents the first application of the TTM to male
HPV vaccination and the first to use this empirical behavior change model to explore
gender differences in vaccine readiness. The current research is presented as three
"studies."
Study 1 aims to present descriptive information about HPV awareness,
knowledge, and perceptions of responsibility for HPV vaccination among young adult
men and women, and subsequently examines these factors as predictors of HPV
vaccination status. In pursuit of this goal, study 1 also aims to develop measures of
HPV-related Knowledge and Perceived Responsibility for HPV vaccination .
Concurrent measurement and examination of men and women enables relevant
gender-based comparisons for all constructs.
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Study 2 aims to develop and test male-specific measures of TTM constructs
indcluding Stage of Change, Decisional Balance, and Self-Efficacy using qualitative
and quantitative measurement development among a sample of 329 young adult men.
Study 3 aims to examine gender invariance with regards to the measures of
readiness for HPV vaccination developed in Study 2 and in past research (Lipschitz et
al., 2013). Measurement structure of the Decisional Balance and Self-Efficacy Scales
are compared using data from 834 men and women.

16

CHAPTER 2

METHODOLOGY

STUDY 1
Recruitment
The target population for this study included men and women between the ages of
18 and 26 years old. Individuals under 18 years old were excluded because of the
study’s emphasis on health-related decision making in the absence of parental consent.
Individuals over 26 years old were excluded because HPV vaccination among is
recommended through the age of 26 only. No participant was excluded on the basis of
race, ethnicity, gender, or sexual orientation.
Recruitment took place during the fall of 2011 and spring of 2012. Men and
women were recruited from undergraduate psychology courses at the University of
Rhode Island and through a national survey sampling company. Participants recruited
through the university received class extra credit as an incentive for participation, and
those recruited through the survey company received monetary compensation based
on the survey company’s payment structure (range: $1.00 - $2.00 for survey
completion). All recruitment and human subject’s procedures were approved by the
university’s institutional review board.
On-campus recruitment resulted in a predominantly female sample due to the
disproportionate number of female students in the targeted psychology courses. In
order to recruit a larger male sample additional men were recruited from a national
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survey sampling company. The male samples from the two sources were compared to
determine whether differences existed in terms of demographics or other key
measures. Chi square analyses revealed the university sample had a higher proportion
of white participants and a higher proportion of participants with health insurance.
Male participants did not differ with regards to ethnicity, awareness of HPV, or Stage
of Change for HPV vaccination.

Participants
The final sample included 834 men and women. Demographic details can be
found in Table 1. Recruitment from the university yielded 505 women and 210 men.
An additional 119 men were recruited from a survey sampling company for a total
combined sample of 505 women (60.6%) and 329 men (39.4%). In terms of race, the
sample was 83% white, 6.8% black, 4.3% Asian, and 5.9% 'Other.' With regards to
ethnicity, 9.1% of the sample identified as Hispanic. Participant's religious affiliations
were 46.9% Catholic, 22.8% Protestant, 9.8% Atheist/Agnostic, 4% Jewish, 9%
'Other,' and an additional 7.6% chose 'Don't Know/Not sure. The median age was 20
years-old. In total 98.2% of the sample was in school, and the majority were college
freshman (51.3%). The median grade point average was in the 3.1 to 3.5 range. Most
participants had health insurance (92.1%). In terms of sexual orientation, 94% of the
sample identified as heterosexual, 1.2% identified as homosexual, 3% as bisexual, and
0,7% as "other." An additional 1.1% did not identify their sexual orientation.
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Measurement Development
The current study evaluated both men and women, thus it was important to have
measures that assessed HPV-related issues relevant to and validated among both
genders. To address this need measures were developed using qualitative and
quantitative methodology. Items were generated through 8 focus groups and 8
cognitive interviews conducted among men and women (men and women were in
different groups). Focus groups aimed to develop measurement content and cognitive
interviews evaluated item comprehension and interpretability. Finally the research
team contacted other investigators conducting research on HPV vaccine uptake to
review the content validity of the instruments. All items generated through male and
female qualitative measurement development are presented in Tables 2 and 3.
Measures
Participants provided demographic information such as gender, age, race,
ethnicity, and religious affiliations.
Stage of Change for HPV vaccination. A short series of questions regarding past
and present HPV-vaccine related behavior were developed to place participants in one
of four mutually exclusive categories for stage of change (PC, C, Prep, A/M). Figure 1
describes the staging algorithm for HPV vaccination. The Action and Maintenance
Stages are combined because maintenance for HPV vaccination is biologically
determined and relapse back to an unvaccinated state cannot occur.
Knowledge. To determine the role of HPV-related knowledge this study assessed
participant’s knowledge of HPV transmission, risk factors, and health consequences
among men and women (e.g., males can develop HPV-related cancers). Fifteen HPV-
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related knowledge were rated by participants as “True," “False,” or “Don’t Know”
The "Don't know" response option was given to discourage guessing. The response
options were then coded to represent correct and incorrect responses (0 =
incorrect/don’t know; 1 = correct). See Figure 2 for final items.
Perceived Responsibility. Seven items assessed participants gender-related beliefs
regarding HPV prevention. Participants were asked the degree to which they agreed
with a given statement (e.g. Men and women should receive the HPV vaccine).
Responses are made on a 5-point scale, ranging from 1 = ‘‘completely disagree’’ to 5
= ‘‘completely agree.’’ See Figure 3 for final items.
Sexual Orientation and Behavior. Past sexual behavior was assessed by asking
participant's their lifetime number of sex partners (open-ended). Condom use was
assessed with one item: "How often do you use condoms when having vaginal or anal
sex?" Response options ranged from 1 = "Never" to 5 = "Always." Sexual orientation
was assessed using a single item asking whether participants identified as
"Heterosexual," "Bisexual," or "Homosexual." An open-ended 'other' category was
also provided.

Statistical Analyses
Chi square tests of independence were used to compare categorical variables
such as HPV-related awareness and HPV vaccination status across demographic
groups. Analysis of Variance (ANOVA) was used to examine mean differences in
continuous variables such as HPV-related knowledge and perceived responsibility
across demographic groups. Categories of race had to be combined in to 'white,'
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'black,' and 'other' to ensure adequate sub-group sizes for analyses. Data normality was
examined using the Shapiro-Wilk test of normality. Non-normal data underwent
logarithmic transformation. Significance of statistical tests and effect sizes are
reported for all analyses. Effect size conventions of small, medium, and large are
assigned according to standards put forth by (Cohen, 1988).
Exploratory and confirmatory data analytic techniques were used to develop the
knowledge and perceived responsibility scales. A split-half sample was used for crossvalidation of measures. The overall Cronbach’s alpha was examined to determine
scale reliability. The exploratory stage of measurement development applied principal
components analysis (PCA) with varimax rotation on item correlation matrixes. The
number of components retained were based on the minimum average partial procedure
(MAP; Velicer, 1976) and parallel analysis (Horn, 1965). The PCA estimated the
number of components and their correlation, factor loadings, and the internal
consistency coefficient for each component. Factor loadings were examined and
poorly loading items (those less than 0.40 or greater than 0.90) and complex items
(those with a factor loading greater than 0.40 on more than one component) were
removed (Redding, Maddock, & Rossi, 2006). Final item selection was determined on
the basis of item clarity, lack of redundancy, and conceptual breadth of theory.
Confirmatory factor analysis was conducted on the second half of the sample
using the components and items indicated in the PCA. Analyses were conducted using
EQS structural modeling computer program (P. M. Bentler, 1993). Fit indices used to
determine the best fitting model included (1) the likelihood ratio chi square statistic,
(2) root mean-square error of approximation (RMSEA), (3) the comparative fit index
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(CFI), and (4) the average absolute standardized residual statistic (AASR). Diagnostic
indicators provided by the analysis were used to detect poorly functioning items.

STUDY 2
This study is a measurement development trial and initial application of the TTM
to HPV vaccination among young adult men. The present study describes the
development of TTM-based measures of Stage of Change, Decisional Balance, and
Self-Efficacy for HPV vaccination which are tailored to men ages 18 to 26 years old.
Data to develop measures of the processes of change were not collected for this
project. The current study builds upon (Lipschitz et al., 2013) work that developed
tailored theory-driven TTM measures for use among young adult women.

Measurement Development
The current study employed a sequential approach to measurement development
(Jackson, 1970; Jackson, 1971; Redding et al., 2006). Measurement development
followed the following steps as defined by (Redding et al., 2006): (a) defining the
construct, (b) writing scale items, (c) expert review, pilot testing, and formative
research, (d) field testing and exploratory analysis (e) data collection, (f) item analysis,
and (g) cross validation and confirmatory analysis. Measurement development
proceeded from a comprehensive literature review to qualitative item development,
focus groups, cognitive interviews, survey administration, and quantitative analysis. It
evaluated the utility of an algorithm approach to determining Stage of Change, and
developed Decisional Balance and Self-Effiacy scales. The patterns of these
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constructs across Stage of Change were compared to those established in previous
research (Hall & Rossi, 2008).

Item Development
Using these female-based measures as a guide (see Lipschitz et al., 2013), item
development for men was conducted. The previously developed female-specific items
were modified and new items were added to the item pool to assess issues more
relevant to men. In addition, pre-existing TTM-based measures from a variety of
health behaviors were reviewed (e.g. blood donation) to ensure adequate breadth of
construct. The items were further refined through qualitative methods such as focus
groups and cognitive interviews. All focus groups and cognitive interviews were
facilitated by male graduate students and/or male undergraduates seniors. Please see
Appendix A for the items for all measures.
Focus Groups. Four focus groups were conducted (N = 28) by recruiting men
between the ages of 18 and 26 from undergraduate psychology classes. Each focus
group was co-facilitated by two male psychology graduate students or advanced
undergraduates. The focus group lasted approximately1.5 hours and participants
received $20 as compensation. The primary purpose of these groups was to assess the
HPV-related beliefs and attitudes of males in the target population to inform
measurement development.
Cognitive Interviews. Following focus groups and item development, four one-onone cognitive interviews were conducted (N = 4). Each cognitive interview lasted
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approximately one hour and participants received $20 as compensation. The primary
purpose of interviews was to determine the clarity and readability of the item pool.

Measures
Stages of change for HPV vaccination. A short series of questions regarding
past and present HPV-vaccine related behavior were developed to place participants in
one of four mutually exclusive categories for stage of change (PC, C, Prep, A/M).
Figure 1 describes the staging algorithm for HPV vaccination. The Action and
Maintenance Stages are combined because the maintenance for HPV vaccination is
biologically determined and relapse back to an unvaccinated state cannot occur.
Decisional Balance. Twenty-two items were designed to represent the pros (11
items) and cons (11 items) of HPV vaccination. Participants were asked to rate how
important each item is in their decision whether or not to get the HPV vaccine (e.g., I
will be protecting myself from a sexually transmitted infection). Responses are made
on a 5-point scale, ranging from 1 = ‘‘not at all important’’ to 5 = ‘‘extremely
important.’’
Self-Efficacy. Thirteen items were designed to assess an individual’s confidence in
their ability to receive the HPV vaccine in a variety of situations that may present
challenges or obstacles to engaging in the behavior (e.g., when it seems too
expensive). Responses are made on a 5-point scale, ranging from 1 = ‘‘not at all
confident’’ to 5 = ‘‘extremely confident.’’

Recruitment
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The target population for this study included men between the ages of 18 to 26
years old. Individuals under 18 years old were excluded because of the study’s
emphasis on health-related decision making in the absence of parental consent.
Individuals over 26 years old were excluded because HPV vaccination among men is
recommended through the age of 26 only. No participant was excluded on the basis of
race, ethnicity, gender, or sexual orientation. Efforts to recruit a diverse sample of
students at the target university were undertaken. The study was advertised at the
multicultural and LGBT (Lesbian, Gay, Bisexual, and Transgender) centers on
campus.
Survey assessment recruitment took place during the fall of 2011 and spring of
2012. Participants were recruited from undergraduate courses at the University of
Rhode Island and through a national survey sampling company. Participants recruited
through the university received class extra credit as an incentive for participation, and
those recruited through the survey company received monetary compensation based
on the survey company’s payment structure (range: $1.00 - $2.00 for survey
completion). All recruitment and human subject’s procedures were approved by the
university’s institutional review board.
Sample Size Determination. Approximately 300 participants were targeted for
recruitment for the survey assessment. Sample size determinations were based on
recommendations for exploratory and confirmatory factor analytic approaches put
forth by (Clark & Watson, 1995; Guadagnoli & Velicer, 1988; S. M. Noar, 2003;
Redding et al., 2006) In general, 200 to 300 participants are recommended for
measurement development purposes when using cross-validation, with fewer subjects
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needed when item loadings are high (.60 - .80) (Redding et al., 2006). Anticipated
factor loadings for this study are medium in magnitude (.40 - .80) based on past TTM
research examining HPV vaccination among women (Lipschitz et al., 2013).
Consent and Human Subjects. For focus groups and cognitive interviews, the
consent form was thoroughly reviewed and all of the questions answered, before
participation began. Facilitators reminded students that their decision to participate
had no bearing on their academic standing or relationship with the university.
Participants were free to leave the group/interview at any time. For students taking
part in the assessment battery portion of this study, informed consent took place
online. The principal investigator’s name and contact information was provided to the
student should questions arise. When participants accessed the study they saw a brief
study introduction followed by the consent form. Students were required to agree to
the consent form prior to accessing the survey.

Participants
The final sample included 329 men. Demographic details can be found in Table 1.
The sample was 76% white (n = 250), and 89.7% non-Hispanic (n= 295). The mean
age was 21 years old (SD = 2.4). The sample was comprised almost entirely of
undergraduate students (87.8%). The average GPA was in the 3.1 to 3.5 range. In
terms of religion the largest portion of the sample identified as Catholic (36.5%) or
Protestant (27.7%). Almost half of men lived in a dormitory or on-campus housing
(47.7%). The majority of the sample had health insurance (87.2%) and most men had
heard of HPV (80.5%). In total, 63.8% (n = 210) of men were recruited from the
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university and 36.2% (n = 119) were recruited from the survey sampling company.
The two samples were compared to determine whether differences existed in terms of
demographics and readiness to receive the HPV vaccine. Chi square analyses revealed
the university sample had a higher proportion of white participants and a higher
proportion of participants with health insurance. Participants did not differ with
regards to ethnicity, awareness of HPV, or Stage of Change.

Statistical Analyses
Data was examined for violations of normality before exploratory and
confirmatory measurement testing and analysis took place. Exploratory and
confirmatory data analytic techniques were employed to study the psychometric
properties of these measures. A split-half sample as used for cross-validation of
measures. The overall Cronbach’s alpha was examined to determine scale reliability.
The exploratory stage of measurement development was applied principal components
analysis (PCA) with varimax rotation on item correlation matrixes. The number of
components retained were based on the minimum average partial procedure (MAP;
(Velicer, 1976) and parallel analysis (Horn, 1965). The PCA estimated the number of
components and their correlation, factor loadings, and the internal consistency
coefficient for each component. Factor loadings were examined and poorly loading
items (those less than 0.40 or greater than 0.90) and complex items (those with a factor
loading greater than 0.40 on more than one component) were removed (Redding et al.,
2006). Final item selection was determined on the basis of item clarity, lack of
redundancy, and conceptual breadth of theory.
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Confirmatory factor analysis was conducted on the second half of the sample using
the components and items indicated in the PCA. Analyses were conducted using EQS
structural modeling computer program (P. M. Bentler, 1993). Fit indices used to
determine the best fitting model included (1) the likelihood ration chi square statistic,
(2) root mean-square error of approximation (RMSEA), (3) the comparative fit index
(CFI), and (4) the average absolute standardized residual statistic (AASR). Diagnostic
indicators provided by the analysis were used to detect poorly functioning items.
External validity of the measures was determined by examining the functional
relationship between Stage of Change and the measures of Decisional Balance and
Self-Efficacy using multivariate analysis of variance. The results were then compared
with construct relationships in other content areas.

STUDY 3
Study 3 aims to examine gender invariance for measures of Decisional Balance
and Self-Efficacy for HPV vaccination. The original measures were developed in
Study 2 and in past research (Lipschitz et al., 2013). Measurement structure of the
Decisional Balance and Self-Efficacy scales are compared using data collected from
834 men and women. See study 1 for methods related to participant recruitment and
demographics.
Sample Size
Sample size consideration for this study took into account that the power to detect
trivial differences in the properties of a measure across groups for larger samples (≥
400 per group) is high; however larger sample sizes may be needed when groups are
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unequal, the number of indicators is low, and factor loadings differ substantially. For
the current research, measures have 1 to 2 factors, and 4 to 6 indicators per factor;
therefore a sample size of 300 or more per group is adequate to capture a meaningful
difference with reference to measurement invariance (Guadagnoli & Velicer, 1988;
MacCullum, Browne, & Cali, 2006).

Measures
Decisional Balance. The measure of Decisional Balance for HPV vaccination was
developed among men and women using the sequential method of scale development
(Jackson, 1970; Jackson, 1971). Items were developed to represent the pros and cons
of HPV vaccination. Participants were asked to rate how important each item is in
their decision whether or not to get the HPV vaccine (e.g., I will be protecting myself
from a sexually transmitted infection). Responses are made on a 5-point scale, ranging
from 1 = ‘‘not at all important’’ to 5 = ‘‘extremely important.’’ The structure of the
measure is a two-factor uncorrelated model with eight items: four items for pros of
HPV vaccination and four items for cons of HPV vaccination. See Figure 4.
Self-Efficacy. The measure of Self-Efficacy for HPV vaccination was developed
among men and women using the sequential method of scale development (Jackson,
1970; Jackson, 1971). Items were developed to assess an individual’s confidence in
their ability to receive the HPV vaccine in a variety of situations that may present
challenges or obstacles to engaging in the behavior (e.g., when it seems too
expensive). Responses are made on a 5-point scale, ranging from 1 = ‘‘not at all
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confident’’ to 5 = ‘‘extremely confident.’’ The structure of the measure single factor
model with five items. See Figure 5.

Statistical Analyses
Measures of Decisional Balance and Self-Efficacy for HPV vaccination were
developed and tested among men and women using qualitative and quantitative
research methods. See Study 2 for a full description of male measurement
development and Lipschitz et al. (Lipschitz et al., 2013) for a description of female
measurement development. These measurement development procedures resulted in a
8-item Decisional Balance measure for women, and a 10-item Decisional Balance
measure for men. Measurement development resulted in a 5-item Self-Efficacy
measure for women, and an 7-item for men. The male measures included additional
items not included in the female measures. These additional items were excluded from
invariance analysis to allow for matched comparisons.
To examine measurement invariance across gender for the constructs Decisional
Balance and Self-Efficacy, perceived risk multiple group CFA was used (Vandenberg
& Lance, 2000). Three levels of invariance were tested in sequential order, with each
level requiring more constraints: 1) Conﬁgural Invariance (unconstrained nonzero
factor loadings); 2) Pattern Identity Invariance (equal factor loadings); and 3) Strong
Factorial Invariance (equal factor loadings and measurement errors). Strong Factorial
Invariance is the most restrictive type of invariance (Horn, McArdle & Mason, 1983;
Meredith, 1993). The two subgroups for the invariance procedures were women (n =
505) and men (n = 329). Gender invariance was determined by examining change in
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model fit as the constraints and degrees of freedom were added using change in CFI. If
the constrained model provides an acceptable fit, then the structural model can be
treated as the “same” for both genders. If the parameters of interest are different, then
the two samples must be treated differently (P. M. Bentler, 1993).
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CHAPTER 3

RESULTS

STUDY 1
Awareness of HPV
Overall, the majority of young adults had heard of HPV (90.2%). Chi Square
analyses indicated women were more likely to have heard of HPV than men (96.4%
vs. 80.5%), χ2 (1) = 56.73, p < .001, Cramer's V = .26, a medium effect. Chi square
tests of race (black, white, other) indicated white participants were more likely to have
heard of HPV relative to other subgroups, χ2 (2) = 16.72, p < .001, Cramer's V = .14, a
small effect. Non-Hispanic participants were more likely to have heard of HPV
relative to Hispanic participants, χ2 (1) = 6.96, p < .01, Cramer's V = .09, a small
effect.

Knowledge Scale
All 15 knowledge items and responses are displayed in Table 4. Most
participants were aware of general facts about HPV (e.g. that a person could be
infected with HPV and not know it); however, participants were less likely to know
specific information about HPV transmission and vaccination (e.g. that person with
HPV can still benefit from HPV vaccination).
Knowledge Scale Exploratory Analyses. The 15 knowledge items were included
in an initial PCA. Varimax rotation on the 15 x 15 matrix of item intercorrelations was
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conducted to determine the factor structure of the scale. A total of two PCAs were
conducted, which ultimately reduced the pool of 15 items to 10. Poorly loading items
were removed ( < .40). See Table 5 for final PCA factor loadings. MAP and parallel
analysis indicated a one-component solution. Internal consistency was good (α = .79).
The single factor accounted for 34.8% of the total variance.
Knowledge Scale Confirmatory Analyses. Two models were tested for knowledge
to determine which model provided the best fit for the data: (1) null model (suggesting
no latent factors and used as a comparative model), and (2) a one factor model. Fit
indices for each model are summarized in Table 6.The one factor model showed the
best fit, and results of the structural modeling produced good factor loadings and good
to excellent model fit, χ 2 (35) = 94.9, CFI = .92, GFI = .96, AASR = .03, RMSEA =
.06. The coefficient alphas of the scale in the confirmatory sample was .79. The final
items and their loadings in the confirmatory sample are shown in Figure 2.
Knowledge Scores across Groups, With regards to the 10-item knowledge scale,
women had higher knowledge scores (M = 6.9, SD = 2.4) than men (M = 5.7, SD =
2.9), F (1, 833) = 40.35, p < .001. The effect for gender was small to medium, R2 =
.046. Knowledge differed significantly by race, F (2, 833) = 3.24, p < .05. This effect
for race was very small, R2 = .008. Participants who identified as white had higher
knowledge scores (M = 6.5, SD 2.6) than those who identified as black (M = 5.9, SD =
2.8) or identified with 'other' racial backgrounds (M = 5.9, SD = 2.8). Hispanic
participants had lower knowledge scores (M = 5.6, SD = 3.1) than those did not
identify as Hispanic (m = 6.5; SD = 2.6), F (833) = 5.2, p < .05. This effect for
ethnicity was very small, R2 = .008.
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Perceived Responsibility
The seven Perceived Responsibility items and the mean responses are displayed
in Table 7. In general men and women agreed all people should be vaccinated, that
insurance companies should pay for the vaccine for both genders and that men and
women should inform their partners if they think/know they have HPV.
Perceived Responsibility Exploratory Analyses. The 7 Perceived Responsibility
items were included in an initial PCA. Varimax rotation on the 7 x 7 matrix of item
intercorrelations was conducted to determine the factor structure of the scale. A total
of three PCAs were conducted, which ultimately reduced the pool of 7 items to 5.
MAP and parallel analysis indicated a one-component solution. See Table 8 for all
final PCA factor loadings. Internal consistency was good (α = .85). The single factor
accounted for 63.1% of the total variance.
Perceived Responsibility Confirmatory Analyses. Two models were tested for
knowledge to determine which model provided the best fit for the data: (1) null model
(suggesting no latent factors and used as a comparative model), and (2) a one factor
model. Fit indices for each model are summarized in Table 6. The one factor model
showed the best fit, and results of the structural modeling produced good factor
loadings and good to excellent model fit, χ 2 (5) = 127.2, CFI = ..89, GFI = .89, AASR
= .04, RMSEA = .24. The coefficient alphas of the scale in the confirmatory sample
was .86. The final items and their loadings in the confirmatory sample are shown in
Figure 3.
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Perceived Responsibility across Groups. With regards to the 5-item Perceived
Responsibility scale, The maximum potential score was 25 and the mean score was
22.07 (SD = 3.86). This indicates there was a potential ceiling effect. Women had
higher Perceived Responsibility scores (M = 23.00, SD = 4.17) than men (M = 20.63,
SD = 23.32), F (1, 833) = 39.78, p < .001. The effect for gender was small to medium,
R2 = .046. Perceived Responsibility did not differ significantly by race, ethnicity, or
insurance status.

HPV Vaccination
In the current sample, 73.7% of women and 26.1% of men had received the full
HPV vaccine series. See Table 1 for percentages of men and women in each Stage of
Change. Chi-square analyses of gender by Stage of Change was significant χ2 (3) =
188.14, p <.001. Women were more likely to be in A/M (i.e. to have received the full
vaccine series) relative to men. Men were more likely to be in PC and C. This was a
large effect, Cramer's V = .47. Chi-square analyses of ethnicity by Stage of Change
was significant. Those who identified as Hispanic were more likely to be in A/M and
less likely to be in P or PC. The effect size was small, Cramer’s V = .10. Chi-square
analyses for race (black, white, other) by Stage of Change was significant χ2 (6) =
13.13, p < .05. Participants categorized as white and 'other' were more likely to be in
A/M relative to black participants. The effect size was small, Cramer’s V = .09. Table
9 presents for effect size for all predictors of Stage of Change.
Insurance status was also related to Stage of Change. Participants who had
insurance were more likely to be in A/M and less likely to be in PC, χ2 (3) = 9.65, p
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=.02, This was a small effect (Cramer’s V = .11). Age was related to Stage of Change
F (3, 833) = 17.28, p < .001, R-squared = .06. This was a medium effect. Follow-up
Tukey tests revealed that participants in A/M (M = 20.18, SD = 1.63) were younger
than those in Precontemplation (M = 21.01, SD = 2.15) and Contemplation (M =
21.56, SD = 2.48) .
Knowledge was related to Stage of Change, F (3, 833) = 3.33, p = .019, Rsquared = .01. This is a small effect. Tukey tests revealed that participants in PC (M =
6.06, SD = 2.87) had lower knowledge scores than those in A/M (M = 6.66, SD =
2.55).
Perceived Responsibility was also related to Stage of Change, F (3, 833) = 20.34,
p < .001, R-squared = .07. This is a medium effect. Tukey tests revealed that
participants in PC (M = 20.67, SD = 3.98) had lower mean scores on Perceived
Responsibility than those in PR (M = 22.71, SD = 3.31) and A/M (M = 22.87, SD =
3.58).
Smoking, which is highly correlated with a number of health risk behaviors, was
associated with Stage of Change F(3, 833) = 4.01, p < .01, R-squared = .01. This is a
small effect. Tukey tests revealed participants in A/M (M = 1.59, SE = .06) smoked
less than those in C (M = 2.12, SD = .08). Sexual behavior was not related to HPV
vaccination. The variables 'Number of sex partners,' 'Frequency of condom use,' and
'Sexual orientation' were examined across Stage of Change and results were not
significant.
Who recommended the HPV vaccine?
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Among vaccinated participants, over half (65.5%) indicated a health-care
provider recommended they receive the HPV vaccine. Mothers were another common
source of vaccine recommendation (29.7%), followed by 'other' (2.2%), 'self' (1.7%),
and fathers (0.9%).

STUDY 2
Exploratory Phase
Decisional Balance. Twenty-two Decisional Balance items were included in the
initial exploratory factor analysis. PCA with varimax rotation on the 22 x 22 matrix of
item intercorrelations was conducted to determine the factor structure of the decisional
balance measure. A total of five PCAs were conducted, which ultimately reduced the
pool of 22 items to 10, with 5 items representing the pros and 5 items representing the
cons of HPV vaccination. MAP indicated a three-component solution while parallel
analysis suggested a two-component solution. After poorly loading items were
removed and the second PCA was conducted both MAP and parallel analysis
indicated a two factor solution. A two factor solution was retained. Examination of the
item content revealed that one factor (five items) clearly reflected Pros of HPV
vaccination and one factor (5 items) clearly represented Cons of HPV vaccination. All
item loadings were above .60 (see Table 10), and the internal consistency was good
for the pros scale (α = .84) and the cons scales (α = .80). The two factors accounted
for 60.1% of the total variance ( 33.9 % for pros and 26.3% for cons).
Self-Efficacy. All 13 self-efficacy items were included in the initial exploratory
factor analysis. PCA with varimax rotation on the 13 x 13 matrix of item
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intercorrelations was conducted to determine the factor structure of the Self-efficacy
measure. Four PCAs were conducted and the initial pool of 13 items was reduced to 7
items. MAP and parallel analysis indicated a one-component solution (see Table 11).
The resulting HPV vaccination Self-Efficacy scale had good internal consistency (α =
.87) and accounted for 56.1% of the total variance.

Confirmatory Model
Decisional Balance. Three models were tested for Decisional Balance to
determine which model provided the best fit for the data: (1) null model (suggesting
no latent factors and used as a comparative model), (2) two-factor uncorrelated model,
and (3) two-factor correlated model. Fit indices for each model are summarized in
Table 12.
The two-factor correlated and uncorrelated model showed good model fit;
however, the two factors had a very low correlation (r = -.006) therefore the
uncorrelated model was chosen. Results of the structural modeling produced good
factor loadings and good to excellent model fit, χ 2 (35) = 82.6, CFI = .92, GFI = .92,
AASR = .06, RMSEA = .09. The coefficient alphas of each scale in the confirmatory
sample for Pros and Cons, were .78 and .83, respectively. The final items and their
loadings in the confirmatory sample are shown in Figure 4.
Self-Efficacy. Two models were tested for Self-Efficacy to determine which
model provided the best fit for the data: (1) null model (suggesting no latent factors
and used as a comparative model), and (2) a one factor model. Fit indices for each
model are summarized in Table 12.
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The one factor model showed the best fit, and results of the structural modeling
produced good factor loadings and good to excellent model fit, χ 2 (14) = 43.4, CFI =
.93, GFI = .92, AASR = .04, RMSEA = .11. The coefficient alphas of the scale in the
confirmatory sample was .83. The final items and their loadings in the confirmatory
sample are shown in Figure 5.

External Validation Stage
Decisional Balance by Stage. Analysis of Variance (ANOVA) revealed that
individuals in different Stages of Change differed significantly on the pros, F (3, 328)
= 10.13, p < .001, η2 = .09, but not on the cons of HPV vaccination, F (3, 328) = 0.56,
p = .64), η2 = .01. Post-hoc analyses revealed that the pros were significantly lower in
Precontemplation than in Preparation or Action/Maintenance. The Cons scale did not
differ significantly across the stages, though the mean scores on this scale showed a
general downward trend from Precontemplation to Preparation. Overall, the pros were
.78 of a standard deviation higher Preparation relative to Precontemplation, and the
Cons were .03 of a standard deviation lower. A graphical representation of T-scores on
the Decisional Balance scales across the stages for HPV vaccination is shown in
Figure 6. Means and Standard Deviations for Pros and Cons across the Stages of Stage
are presented in Table 13.
Due to the lack of significant variability in the cons scale, an exploratory followup analysis was conducted on all of the original cons items. Analysis of Variance
(ANOVA), with a bonferroni adjustment, revealed that only one item differed
significantly across Stages of Change, F (3, 328) = 12.04, p < .001, η2 = .10. This
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item (The vaccine would cost too much money) was lower in Precontemplation and
Contemplation relative to Preparation and Action/Maintenance. No other items were
significant.
Self-Efficacy by Stage. Analysis of variance (ANOVA) conducted to examine the
Self-Efficacy scale across the Stages of Change revealed significant differences, F (3,
328) = 7.09, p < .001, η2 = .06. A graphical representation of self-efficacy T-scores
across stage is shown in Figure 7. Means and Standard Deviations for Self-Efficacy
across the Stages of Stage are presented in Table 13. Post-hoc analyses revealed that
Self-Efficacy was lower in Precontemplation than in Preparation or
Action/Maintenance.

STUDY 3
To test for factorial invariance, structural equation modeling (SEM) was
employed using EQS 6.1 software (P. M. Bentler, 1993). The following indices were
used to analyze the ﬁt of the invariance models: Comparative Fit Index (CFI), Normed
Fit Index (NFI), Nonnormed Fit Index (NNFI), and Root Mean Squared Error of
Approximation (RMSEA). The χ2 values and χ2 differences are reported, but
alternative fit indices are relied upon for assessing model fit. The χ2 test is too
sensitive to trivial fluctuations and differences in general and in the context of
invariance testing specifically (P. M. Bentler & Bonett, 1980; Hu & Bentler, 1999;
Kline, 2005; Little, 2013). The CFI, NFI, and NNFI indicate how well a model ﬁts the
data with values from 0 to 1, with larger values indicating a better ﬁt. Values greater
than .90 indicate good ﬁt and values greater than .95 indicate very good ﬁt (P. M.
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Bentler, 1992; Kline, 2005). For RMSEA, smaller values indicate better ﬁt, with
values less than 0.1 indicating good ﬁt and values less than 0.05 indicating very good
ﬁt (Browne & Cudeck, 1993; Kline, 2005). The indicators of ﬁt considered in the
present study (CFI, NFI, NNFI, RMSEA) were the same indices utilized by (Ward,
Velicer, Rossi, Fava, & Prochaska, 2004) and (Babbin et al., 2011) in papers
evaluating the psychometric properties of Decisional Balance inventories for health
behavior change. Additionally, the difference in CFI between the model and the
previous (lower) level of invariance (ΔCFI) was calculated. A value of −0.01 or less
indicates good model fit (Cheung & Rensvold, 2002). No constraints were dropped in
any of the models to achieve a better ﬁt.

Decisional Balance
Results for Decisional Balance invariance can be seen in Table 14. Pattern
Identity Invariance was a good fit for the data (CFI = .949, NFI = .929, NNFI = .940,
RMSEA = .076). Change in CFI was .016 as constraints were added to the model,
which indicates a reduction in model fit. The highest level of invariance, strong
factorial, did not fit the data.

Self-Efficacy
Results for Self-Efficacy invariance can be seen in Table 14. Pattern Identity
Invariance was a very good fit for the data (CFI = .982, NFI = .972, NNFI = .976,
RMSEA = .065). Change in CFI revealed a .005 decrease as constraints were added,
further supporting invariance at this level. The highest level of invariance, strong
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factorial was a good fit for the data (CFI = .966, NFI = .953, NNFI = .953, RMSEA =
.077). Change in CFI revealed a .016 decrease in fit as parameters were added to the
model.

Scale Reliabilities
Since Pattern Identity and Strong Factorial Invariance held for each of the sample
comparisons, the factor structure is reported for the combined male and female sample
(see Figure 8 and Figure 9). In the total sample, coefficient alpha was 0.87 for Pros,
0.76 for Cons, and 0.86 for Self-Efficacy.
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CHAPTER 4

DISCUSSION

Study 1
The current study reports rates of HPV vaccination in a sample of young adults
and explores demographic and psychosocial correlates of vaccination such as gender,
race, ethnicity, HPV-related awareness, knowledge, and perceived responsibility. It is
one of few studies to compare male and female attitudes and opinions about HPV
vaccination and adds to an emerging body of literature reporting rates of HPV vaccine
uptake among young adult men.
HPV vaccination
Results from Study 1 indicate that 73.7% of women and 26.1% of men completed
the full HPV vaccine series. These rates of vaccination are very similar to those
reported for adolescents in Rhode Island, where the majority of the data were
collected. In Rhode Island; 76.1% of adolescent females and 24.6% of adolescent
males have received ≥ 1 dose of the vaccine in 2011 (Centers for Disease Control and
Prevention, 2012). Data for adults were not available for comparison. These
vaccination rates, however, are high relative to national averages. Nationally, 43.1%
of adult women and 2.8% of adult men received ≥ 1 dose of the vaccine in 2011
(Centers for Disease Control and Prevention, 2013). Taken together, these data
indicate that vaccination in Rhode Island are high relative to national averages, and
that in some geographic regions and subpopulations approximately 1/4 of men and 3/4
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of women have received at least one dose of the HPV vaccine. These findings are
encouraging considering that some researchers concluded that male HPV vaccination
was nearly "non-existent" one year after licensure (Reiter, McRee, Kadis, & Brewer,
2011). Now, three years after licensure male vaccination appears to be gaining
momentum.
Results of Study 1 indicate substantial variation in HPV vaccination rates across
demographic subgroups. As indicated, women were three times more likely to be
vaccinated than men. These differences were statistically significant and the effect size
was large. Within the entire study sample (men and women combined) black
participants were less likely to have received the HPV vaccine relative to other racial
subgroups; 45% of black participants were vaccinated compared to 56% of white
participants, a difference of 11 percentage points. This degree of difference is large
from a public health perspective (J. S. Rossi, 2013). Across research studies, black
race is consistently linked with a decreased likelihood of HPV vaccine initiation and
completion, underscoring the need for targeted interventions to increase vaccination
among black men and women (Cook et al., 2010; Ford, 2011; Keenan et al., 2012).
With regards to ethnicity, Hispanic participants were more likely to be vaccinated
than other ethnicities; 62% of Hispanic participants had completed the HPV vaccine
compared to 54% of non-Hispanic participants. Rates of HPV vaccination among
Hispanic populations are variable across studies. Several studies report Hispanic
populations are more likely to report vaccination or intentions to receive the HPV
vaccine relative to other ethnic groups (Cook et al., 2010; Daley et al., 2011), while
other studies report Hispanics are less likely to receive the vaccine (Ford, 2011).
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Sociodemograhic and cultural explanations for these differences are unclear and may
be related to differences in study sampling as well as the vast heterogeneity within the
Hispanic population. Additional research is needed to clarify these research
discrepancies. Overall, these findings underscore the importance of understanding
potential vaccine disparities across racial and ethnic groups, particularly because black
and Hispanic men and women have higher rates of HPV-related cancers and mortality
relative to non-Hispanic whites (Hariri et al., 2011; Hernandez et al., 2008; Ortiz et al.,
2010).
The current study also found younger participants were more likely to be
vaccinated than older participants. Adolescent vaccination rates have consistently
increased since vaccine licensure and outpaced adult vaccination rates (Centers for
Disease Control and Prevention, 2011a; Centers for Disease Control and Prevention,
2012); thus younger cohorts are more likely to be vaccinated. These findings indicate
there is an ongoing need for interventions and health promotion efforts that encourage
"catch-up" vaccination among adults. While early adolescence is the ideal time for
HPV vaccination, young adult vaccination can still have a substantial public health
impact. In one epidemiological trial, 60% of unvaccinated sexually active young
adults (18 years old or older) contracted HPV at some point over a 5-year period,
indicating that vaccination during young adulthood can prevent a substantial portion of
HPV infection and transmission (Baseman & Koutsky, 2005).
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Who recommends the HPV vaccine?
The majority of vaccinated participants (65.5%) cited doctors and health care
providers as the source of vaccine recommendation. Those with health insurance were
also more likely to be vaccinated. These findings are consistent with past research
indicating physician recommendation is one of the most important factors that predicts
HPV vaccination (Gilkey, Moss, McRee, & Brewer, 2012; Reiter, Brewer, & Smith,
2010; Reiter, Brewer, McRee et al., 2010). In fact, parents of adolescents are almost
five times more likely to initiate vaccination when a physician recommends it (Ylitalo,
Lee, & Mehta, 2012). Lack of physician recommendation may even perpetuate
vaccine disparities. Researchers have found physicians are less likely to recommend
the HPV vaccine to boys and ethnic/racial minorities, and this lower likelihood of
recommendation is associated with lower vaccination rates in these groups (Gilkey et
al., 2012; Ylitalo et al., 2012). Considered together, these findings indicate more
effective methods should be implemented to promote vaccination recommendation by
health care providers across all demographic groups.
Mothers were the second most common source of vaccine recommendation.
Among vaccinated participants 29.7% indicated their mother recommended the
vaccine. Only a very small percentage of participants indicated other sources of
recommendation such as 'self' or fathers. These findings underscore the importance of
mothers in promoting/facilitating HPV vaccination, while it appears fathers are rarely
involved in the vaccination decision making process. These findings can inform
future parent-based interventions; however among young adult populations parents
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may have less influence over health care decisions and thus physician or media-based
HPV vaccine promotion efforts may be more effective in this group.

Sexual Orientation and Sexual Behavior
Sexual orientation, number of lifetime sexual partners, and frequency of condom
use did not predict HPV vaccination status. However, the current sample was 95%
heterosexual, thus the sample of gay and bisexual men and women may have been too
small to detect potential differences in attitudes and behavior related to HPV
vaccination across groups.

HPV-Related Awareness and Knowledge
Results indicated that HPV awareness was high, approximately 96% of women
and 80% of men had heard of HPV. Comparing these rates to past research suggests
that HPV awareness may be increasing with time. As recently as 2007 a review of
seven studies reported only 42% (range 0%–72%) of respondents were aware of HPV
(Brewer & Fazekas, 2007).
To determine participants knowledge of HPV, the current study developed and
tested an HPV-related knowledge scale using exploratory and confirmatory analyses.
Measurement development resulted in brief, reliable, and valid unidimensional
measure. The scale was internally consistent, Cronbach's alpha was .79. All factor
loadings were within an acceptable range (.41 to .62). This scale assesses individual's
knowledge of HPV-related disease, prevention, and transmission. It includes issues
relevant to both male and female sexual health.
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Using the total knowledge scale score as a dependent variable, analyses indicated
women had higher overall knowledge scores than men, and the effect size for this
finding was in the medium range. Participants who identified as white were more
likely to have heard of HPV and had higher knowledge scores relative to other racial
subgroups. Non-Hispanic participants were more likely to have heard of HPV and had
higher knowledge scores than those who identified as Hispanic. The majority of
participants were aware of basic facts about HPV such as 'HPV vaccination could help
prevent HPV infection' (85.9%) and 'a person could be infected with HPV and not
know it' (82.6%). This study also revealed that participants had key knowledge gaps
with regards to specific information about HPV infection and transmission. For
example, most men and women incorrectly believed that HPV could only be spread
through sexual intercourse and that condoms fully prevent against HPV transmission.
These findings are consistent with past research that reports critical knowledge deficits
with regards to HPV viral transmission, prevention, screening, and treatment among
young adults (Allen et al., 2009; Licht et al., 2010; Sandfort & Pleasant, 2009; Wong
& Sam, 2010). Knowledge scores were also related to readiness to receive the
HPVvaccine. Those in earlier Stages of Change had lower knowledge scores than
those in Action/Maintenance, however this effect was small.
Given the growing rates of HPV-related cancers in men and the impact of HPV
on the population as a whole, increasing knowledge is one way to increase vaccine
initiation; however, interventions that target knowledge have not successfully
increased vaccination rates (Dempsey et al., 2006; Gerend & Barley, 2009). From a
TTM-perspective increasing knowledge (i.e. Consciousness Raising) can start the
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change process, but once knowledge is obtained individuals must use other cognitive
and behavioral processes to move through the Stages of Change and take action on a
given behavior (J. O. Prochaska et al., 1988; J. O. Prochaska & DiClemente, 1983).
Thus, future interventions should ensure that young adults are educated about HPV but
also include other empirically-supported behavior-change variables.

Perceived Responsibility
The current research developed a measure to assess Perceived Responsibility for
HPV prevention among young adult men and women. The measure of Perceived
Responsibility adds to the literature by providing a tool to assess the relative
importance individuals place on gender-specific HPV prevention efforts at the
individual and societal level. Measurement development using exploratory and
confirmatory analyses resulted in a brief, reliable, unidimensional scale. The scale was
internally consistent. Cronbach's alpha was .86. All factor loadings were within an
acceptable range (.62 to .85).
The Perceived Responsibility measure answers important questions about young
adult's views regarding HPV prevention. Results of the current study indicate the
majority of young adults 'agree' or 'strongly agree' that men and women should be
vaccinated for HPV, that insurance should pay for vaccination for men and women,
and that men and women should tell their partner's if they know/suspect they have
HPV. The average participant rating of items on the Perceived Responsibility measure
was 22 out of a maximum of 25 (with higher numbers indicating greater perceptions
of responsibility). These data indicate there is a high level of interest and public
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support for HPV vaccination and insurance coverage among young adults. The
majority of young adults agree that vaccination is important from a public health
perspective for both genders and believe that individuals and society have a
responsibility to prevent HPV transmission.
Using the mean score for Perceived Responsibility as a dependent variable,
analyses indicate that women had higher Perceived Responsibility scores than men.
The effect for gender was small to medium. Differences across Stage of Change were
also observed. Participants in Precontemplation had lower mean scores on Perceived
Responsibility than those in Preparation and Action/Maintenance, indicating that
unvaccinated individuals had lower Perceptions of Responsibility for HPV prevention
than those who were vaccinated or preparing to receive the vaccine in the next 30
days. The effect size was in the medium range. The pattern of Perceived
Responsibility across Stage of Change followed a similar patter to that of SelfEfficacy. It was higher in Preperation and Action relative to Precontemplation and
Contemplation. This indicates that there may be some similarities between these two
constructs. This should be explored in future research.
Perceived Responsibility did not differ significantly by race, ethnicity, or
insurance status. These findings indicate that perceptions of social and individual
responsibility for HPV prevention are associated with an individual's vaccination
status and gender. While this does not indicate direction of causality, it is intriguing
from a clinical stand point. Future research should investigate whether perceptions of
responsibility can be used to promote HPV vaccination in future interventions. In
other areas of health, such as HIV prevention, messages about personal responsibility
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are common elements of health promotion campaigns (Wolitski, Bailey, O'Leary,
Gomez, & Parsons, 2003). These messages could be useful in HPV interventions
because they appeal to people’s desire to uphold individual and community standards
that promote personal health or the well-being of others.

Strengths and Limitations
This study had many strengths and limitations. Limitations include sample
homogeneity. The majority of subjects were white young adults recruited from a
single university in the northeastern United States; thus findings may not generalize to
other groups. An additional limitation of the current research was recruitment
inconsistency across the male and female sample. All women and two thirds of men
were recruited from a single university. The remaining one third of men were
recruited from a national survey company due to low recruitment rates at the target
university. These differences in recruitment could have introduced differences
between the male and female sample. However, comparisons of men across
recruitment sources indicated consistency with regards to key dependent variables
(e.g. vaccination rates).
Strengths of this study include recruitment of a large sample which enabled
comparisons of demographic subgroups on key dependent variables. The measures of
Knowledge and Perceived Responsibility add important HPV-related measures to the
literature. To our knowledge few, if any, systematically developed scales have been
developed to assess these constructs among men and women. This research represents
an important step in understanding HPV-related knowledge, beliefs, and vaccination
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among young adults, highlighting differences across gender, race, ethnicity, and age.
It adds to a growing body of literature that attempts to understand motivation and
decision-making related to vaccination among young adults and can inform future
research and intervention development.

STUDY 2
The current research represents the first study to develop Transtheoretical Modelbased measures of HPV vaccination among young adult men. The study resulted in
internally and externally valid measures of Decisional Balance (Pros and Cons) and
Self-Efficacy for HPV vaccination. Construct validity was evident for two of the three
TTM scales (Pros and Self-Efficacy). These two scales demonstrated known-groups
validity across stages of HPV vaccination.
Decisional Balance
Results supported a two-factor uncorrelated model for Decisional Balance. One
factor was comprised of five 'Pros' items and the other factor was comprised of five
'Cons' items. Cronbach's alpha was good for both scales; .83 for Pros and .78 for Cons.
External validity was tested by examining the variability in Pros and Cons across the
Stages of Change to determine whether the scales followed patterns observed in past
research. Research has shown that an increase in Pros from Precontemplation to
Preparation, a decrease in Cons, and a corresponding "cross-over" in which Pros begin
to outweigh Cons in the Preparation Stage of Change (Hall & Rossi, 2008; J. O.
Prochaska et al., 1994). External validity of the Pros scale was supported. Pros was
significantly higher Preparation that Precontemplation. The predicted cross-over did
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occur, in which the Pros of behavior change begin to outweigh the Cons in the
Preparation Stage. These findings are consistent with TTM theory and past results of
measurement development for HPV vaccination among women (Lipschitz et al.,
2013).
The magnitude of change in Pros and Cons across the Stages of Change was
examined and compared with established standards demonstrated in past TTM
research. In a meta-analysis of over 48 health behaviors, the average increase in Pros
from Precontemplation to Preparation was 1.0 standard deviation. The average
decrease in Cons from Precontemplation and Maintenance was .5 standard deviation
units (Hall & Rossi, 2008). In this study the increase in Pros was .78 standard
deviation units, and the decrease in Cons scaled was .03 standard deviation units.
Thus, magnitude and direction of change in Pros adhered fairly closely to the past
standard; however, Cons did not show the predicted decrease across Stage of Change.
These findings suggest that the broader Cons construct does not play a powerful role
in the decision to receive the HPV vaccination series for men. However, one specific
'Con,' cost of vaccination may play an important role. In a follow-up post hoc analysis
of the original Cons items, cost of vaccine was the only item that was significantly
related to Stage of Change. This item, "the vaccination would cost me too much
money," was more likely to be perceived as a disadvantage of vaccination among men
in Precontemplation and Contemplation relative to men in Preparation and Action.
These findings, though preliminary, suggest that cost is a major barrier to vaccination
among men. Past research also suggests that out-of-pocket vaccine cost is so high, that
interventions focused on motivation or health beliefs will only be effective if vaccine
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cost is reduced (Liau et al., 2012). Thus, reducing the cost of the HPV vaccine should
be a public health priority.

Self-Efficacy
Exploratory and confirmatory analyses resulted in a brief reliable measure of
Self-Efficacy for HPV vaccination. Analyses supported a single factor model as the
best fit for the data. The final scale was comprised of seven items with fit indices
falling within an acceptable range (.49 to .75). The scale was internally consistent,
Cronbach's alpha was .83. External validity was demonstrated by examining the
variability in Self-Efficacy across the Stages of Change. Self-Efficacy is expected to
increase from Precontemplation to Preparation (J. S. Rossi & Redding, 2001). This
expected increase was observed. Self-Efficacy increased .8 of a standard deviation
from Precontemplation to Preparation.

Limitations and Future Directions
Limitations of the current study include recruitment of a predominantly white
college-attending sample. These constructs may not generalize to other populations. In
addition, the cross-sectional nature of this study did not enable tests of predictive
validity. The research supported the internal validity of all constructs, however the
Cons scale did not vary across Stages of Change in predicted ways indicating a lack of
construct validity for this scale. Additional research should examine whether Cons is a
reliable predictor of vaccination among men, or whether cost of vaccination is a more
effective intervention target.

54

The current research represents a first-step in developing a TTM-based
intervention to promote HPV-vaccination initiation and completion among young
adult men. TTM-based computer-tailored interventions are based on psychometricallysound measurement instruments that link empirically-supported constructs with
readiness for health behavior change (S. M. Noar, Benac, & Harris, 2007). The results
reported here highlight several constructs that can potentially be targeted to increase
vaccination rates among the population of interest. Based on study results,
interventions should aim to (1) increase perceived advantages of vaccination among
individuals in early Stages of Change, (2) help men understand vaccine cost and
resolve payment issues, and (3) increase Self-Efficacy by addressing perceived
barriers to vaccination. Future longitudinal research should determine whether these
constructs can be used to predict and increase vaccination through tailored
interventions.

STUDY 3
Study 3 is the first study to compare TTM-based measures of HPV vaccination
across male and female subgroups. The current study examined factorial invariance
for two TTM-based measures of Decisional Balance and Self-Efficacy developed
among young adults. Both measures demonstrated factorial invariance across gender
for Pattern Identity Invariance. Pattern identity Invariance requires that factor structure
and factor loadings are constrained in the model. All fit indices, NFI, NNFI, CFI, and
RMSEA consistently showed good fit across subgroups The ΔCFI indicator was
below the cutoff (- .01) for Self-Efficacy indicating very good fit as constraints were
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added to the model. Change in CFI was slightly above the cut-off for Decisional
Balance (-.016); however, fit criteria should be considered in concert to determine
overall fit (Little, 2013). For Decisional Balance four out of five criteria indicated
good fit for Pattern Identity Invariance. The highest level of invariance, Strong
Factorial Invariance was demonstrated for the Self-Efficacy measure only. Strong
Factorial Invariance requires that factor structure, factor loadings, and error terms are
constrained in the model. Reliability of the scales was good. Cronbach's coefficient
alpha was 0.87 for Pros, 0.76 for Cons, and 0.86 for Self-Efficacy.
The demonstration of Pattern Identity Invariance for Decisional Balance and SelfEfficacy indicates that the factor structure and loadings for both the Decisional
Balance and Self-Efficacy measures are invariant across gender. Accordingly, these
measures can be used in their current form to simultaneously assess men and women
and make meaningful mean comparisons. The demonstration of Strong Factorial
Invariance for Self-Efficacy indicates the invariance of this measure is even more
robust and confidence in invariance across gender is high.
Confirming the invariance of a factor model is beneficial to conducting valid
research and is important for implementing clinical interventions based on the TTM.
Evidence of Strong Factorial Invariance indicates that measures of the latent
constructs Decisional Balance and Self-Efficacy are the same across groups. This does
not mean that group means are the same, but that group means extrapolated from the
measures can be compared in meaningful ways. By demonstrating factorial invariance,
researchers can be confident that homogeneity among subgroups will not distort the
results of future tests.
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The current research promotes the use of HPV Decisional Balance and SelfEfficacy measures among men and women concurrently. The consistency of the
measurement model across these groups provides strong empirical support for the
construct validity of the scales. Invariant, psychometrically sound measures such as
the HPV Vaccination Decisional Balance and Self-Efficacy measures are needed when
developing effective tailored prevention interventions to increase HPV vaccination
among men and women.

Limitations and Future Directions
Limitations of this study involve sampling characteristics and recruitment
techniques as discussed previously (see Study 1). Differences in recruitment between
male and female sample had the potential to introduce sample differences that could
influence measurement invariance. However, in the current study, these differences in
sampling did not appear to impact analytic results. Invariance was demonstrated
despite sampling differences.
Sample size was not adequate to examine measurement invariance across all
relevant subgroups. Future research should determine whether these measures assess
the same underlying constructs across racial, ethnic, and student vs. non-student
populations.
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CHAPTER 5

CONCLUSION

Collectively, these three studies add to an emerging body of literature examining
male and female attitudes, knowledge, and intentions to receive the HPV vaccine.
This study reports the highest rates of HPV vaccination among young adult men in the
literature. This is encouraging given the recent licensure of the vaccine and concerns
about public interest in the male vaccine. These studies collectively indicate that men
are interested in vaccination, willing to receive the vaccine, have basic knowledge
about HPV, and perceive HPV prevention as their responsibility. The current research
also adds to the literature by presenting data collected from men and women following
approval of the HPV vaccine for men. Gender comparisons, like those reported here,
are uncommon in the literature, but are important for understanding the attitudes and
behaviors of men and women post-HPV licensure.
The current research also adds several new TTM-based measures of male HPV
vaccination to the literature including HPV-related Stage of Change, Decisional
Balance, and Self-Efficacy. These measures can be used to understand behavior
change, and are designed to predict and promote vaccination in future research. The
Strong Factorial Invariance demonstrated in Study 3 further validates the use of these
measures among both men and women and increases their research utility. Future
research can use these measures to make meaningful comparisons of Pros, Cons, and
Self-Efficacy across gender.
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Implications for Diverse Populations
Results of this study highlight key disparities in HPV vaccination and education.
Black participants and men had lower likelihood for vaccination and lower overall
knowledge scores than women and participants of other racial groups. The Hispanic
sample had higher vaccination rates, but lower awareness and knowledge of HPV
vaccination. Vaccination promotion and HPV prevention efforts among these groups
are needed, particularly considering black and Hispanic populations have the highest
rates of several HPV-related morbidity and mortality. This disproportionate impact on
underserved population is unacceptable given that HPV-related mortality is largely
preventable through HPV vaccination, pap smear screening, and early treatment.
Reducing this health disparity will likely require intervention at the individual and
population level through public health campaigns and targeted intervention programs.
These interventions should specifically target demographic subgroups using
culturally-tailored approaches because they be more effective in preventing sexually
transmitted infections than a one-size fits all approach (R. J. DiClemente et al., 2004).
In the area of HPV-related vaccination and prevention, men are also an
underserved population. The inclusion of men in this study is important for the
advancement of men's sexual health issues. Traditional emphasis on women’s health
and family planning has resulted in men’s sexual health needs being de-emphasized.
Very little research has targeted the reproductive and sexual health of men,
particularly heterosexual men (Sternberg & Hubley, 2004). Promoting men and
women's awareness, knowledge and access to the HPV vaccine is consistent with non-
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discriminatory projects and acceptable and sustainable sexual health education and
programs (Collumbien & Hawkes, 2000). Additional efforts to include men in HPV
prevention and education are warranted considering women are still three times more
likely to be vaccinated than men several years after approval of the male vaccine.

Next Steps
The next step in this research, in addition to those already listed, is to develop
and test a TTM-based computer-tailored intervention to increase HPV vaccination
among men. This intervention will be informed by the empirically-supported
measures developed herein. Constructs not included in traditional TTM-based
interventions, such as Knowledge and Perceived Responsibility, should also be
included given positive associations between these measures and Stage of Change.
Intervention development and testing could incorporate these measures in essential
ways. The measures can be uses for pre- and post-test assessment, the items can
inform intervention content, and measurement-based statistical cut-offs can be
calculated for intervention tailoring. Given the strong link between health-care
provider recommendation and HPV vaccination behavior, a clinic-based intervention
may be an ideal point of access. Web-based or tablet delivery could bring the
intervention to clinic waiting rooms. This study represent the first stage in such a
program of research and provides theoretically- and empirically-based assessments to
serve as its foundation.
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Table 1. Demographics of Male and Female Sample
MALE

FEMALE

N

%

N

%

Precontemplation
Contemplation
Preparation
Action/Maintenance

178
48
17
86

54.1
14.6
5.2
26.1

92
20
21
372

18.2
4.0
4.2
73.7

White
Black
Asian
American Indian/Alaskan Native
Hawaiian/Pacific Islander
Other

250
34
28
1
0
16

76.0
10.3
8.5
0.3
0.0
4.9

442
23
8
0
3
29

87.5
4.6
1.6
0.0
0.6
5.7

Not Hispanic
Hispanic/Latino

295
34

89.7
10.3

463
42

91.7
8.3

Catholic
Protestant
Jewish
Muslim
Buddhist
Hindu
Atheist/Agnostic
Don’t Know/Not Sure
Other

120
91
11
1
4
1
58
26
17

36.5
27.7
3.3
.3
1.2
.3
17.6
7.9
5.2

271
99
22
3
2
0
24
37
47

53.7
19.6
4.4
0.6
0.4
0.0
4.8
7.3
9.3

Freshman
Sophomore
Junior
Senior
5th Year Undergraduate
Other
Not Currently In School

127
64
45
41
12
10
30

38.6
19.5
13.7
12.5
3.6
3.0
9.1

301
74
72
43
10
5
0

59.6
14.7
14.3
8.5
2.0
1.0
0.0

Stage of Change

Ethnicity

Hispanic

Religion

Year in School
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Table 2. Original and Final Items for Male and Female Decisional Balance Measure
Original Items
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Protecting myself from HPV would make me feel good.
I would be protected from getting certain cancers and genital warts.
I would be protecting myself from getting an STD.
I would be less likely to spread HPV.
I would be perceived as more responsible if I were to get vaccinated.
Getting the vaccine could help keep HPV from spreading.
PROS
Getting the vaccine would reduce the risk of future partners developing genital warts or cancer.
Having the vaccine would allow future partners to feel more comfortable having sex with me.
My doctor would approve of me getting the vaccination series.
People close to me would be happy with me if I received the vaccination series.
I would be a role model for my peers if I got vaccinated.
Getting vaccinated would reduce my current/future partner(s) fear of contracting HPV.
My parents would know I was having sex if I got vaccinated.
Receiving the series of three shots would take too much time.
It would be too embarrassing to talk to my parents or doctor about getting vaccinated.
My partner would not approve of me receiving the vaccine.
I would not fit in with my friends because they have not received the vaccine.
CONS
Getting the vaccine would make me uncomfortable because I hate shots.
The vaccination would cost me too much money.
The vaccination could cause side-effects and unknown long-term risks.
I would cause shame to my family/religion.
People would think I was having risky sex if I got vaccinated.
Note. Bold Items were included in original male survey development only

Final
Male
X
X
X
X
X

Final
Female
X
X
X
X

X
X
X
X
X

X
X
X
X

Table 3. Original and Final Items for Male and Female Self-Efficacy Measure
Original Items
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When I think about the possible side effects of the vaccine.
When I anticipate that the shot will be painful.
When my family is against me getting vaccinated.
When I anticipate feeling faint or dizzy when getting the shot.
When it is inconvenient.
When it is too expensive.
When my significant other does not want me to get the vaccine.
When I don’t know how others will respond to my getting the vaccine.
When I have to go somewhere unfamiliar to get the shot.
When my friends are unsupportive of me getting the HPV vaccine.
When it seems too difficult to fit into my schedule.
When I am stressed.
When I know my partner(s) has already been vaccinated
Note. Bold Items were included in original male survey development only

63

Finale
Male
X
X
X
X
X
X
X

Final
Female
X
X
X
X
X
X

Table 4. Knowledge Items and Accuracy of Responses
Men

Women

Total

Answ
er

%
correct

%
correct

%
correct

1

A person may be infected with HPV
and now know it

True

76.9

86.3

82.6

2

HPV does not cause cervical cancer

False

44.4

72.7

61.5

3

Vaccination can help prevent HPV
infection in men and women

True

79.3

90.1

85.9

4

HPV can lead to cancers of the anus,
vagina, throat, and mouth

True

47.7

60.4

55.4

5

Only women are at risk for health
problems related to HPV

False

66.3

82.2

75.9

6

HPV can only be spread through sexual
intercourse

False

23.7

28.7

26.7

7

HPV is transmitted or spread via
genital contact

True

60.5

67.7

64.9

8

Men are not routinely tested for HPV

True

49.2

48.7

48.9

9

Genital warts are unrelated to HPV

False

42.2

45.9

44.5

10

For most people an HPV infection goes
away on its own

True

9.1

6.7

7.7

11

A person cannot transmit HPV is
he/she does not have symptoms

False

60.2

77.6

70.7

12

Most people with HPV have no visible
signs or symptoms

True

45.3

58.6

53.4

13

Condoms fully prevent against HPV
transmission

False

43.8

52.5

49.0

14

People who already have HPV cannot
benefit from the HPV vaccine

False

25.2

28.3

27.1

15

If you started the HPV vaccination series
and missed a shot, you have to re-start
False
the series from the beginning

16.4

18.0

17.4

Note. Bolded items are included in the final scale.
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Table 5. Results of Principal Component Analysis for Knowledge
Scale
Factor
Knowledge Scale (α = 0.79)
Loading
A person may be infected with HPV and now know it.

0.60

HPV does not cause cervical cancer.

0.61

Vaccination can help prevent HPV infection in men
and women.

0.55

HPV can lead to cancers of the anus, vagina, throat,
and mouth.

0.65

Only women are at risk for health problems related to
HPV.

0.59

HPV is transmitted or spread via genital contact.

0.58

Men are not routinely tested for HPV.

0.48

Genital warts are unrelated to HPV.

0.62

A person cannot transmit HPV is he/she does not
have symptoms.

0.61

Most people with HPV have no visible signs or
symptoms.

0.60
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Table 6. Fit Indices for Knowledge and Perceived Responsibility Models
χ2 (df)

GFI

CFI

AASR RMSEA

830.76 (45)*

---

---

---

---

94.9 (35)*

0.96

0.92

0.03

0.06

1077.6 (10)*

---

---

---

---

Knowledge
Model 1: Null Model
Model 2: one factor model
Perceived Responsibility
Model 1: Null Model

Model 2: one factor model
127.2 (5)*
0.89
0.89 0.04
0.23
Note. N = 171, χ2 = chi square, df = degrees of freedom, GFI = goodness of fit,
index, CFI = comparative fit index, AASR =average absolute standardized residual
statistic, *p < .001
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Table 7. Means of Perceived Responsibility Items among Men and Women
Women

Men

M

SD

M

SD

1

Anyone engaging in sexual activity (male
or female) should get the HPV vaccine

3.97

1.08

3.61

1.06

2

If women get the HPV vaccine men don't
need to

1.58

1.03

2.34

1.11

3

Men AND women should receive the
HPV vaccine

4.18

1.02

3.79

1.03

4

Insurance companies should pay for the
HPV vaccine for MEN

4.38

1.01

4.11

1.14

5

Insurance companies should pay for the
HPV vaccine for WOMEN

4.51

0.90

4.27

1.04

6

A woman should tell her partner(s) if
she knows/suspects she has HPV

4.54

0.90

4.28

1.07

7

A man should tell his partner(s) if he
knows/suspects he has HPV

4.46

1.00

4.19

1.12

Note. Bolded items were included in the final Perceived Responsibility Scale
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Table 8. Result of Principal Components Analysis for Perceived
Responsibility Scale
Perceived Responsibility Scale (α = 0. 85)
Men AND women should receive the HPV vaccine
Insurance companies should pay for the HPV vaccine for
MEN
Insurance companies should pay for the HPV vaccine for
WOMEN
A woman should tell her partner(s) if she knows/suspects
she has HPV
A man should tell his partner(s) if he knows/suspects he
has HPV
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Factor
Loading
0.723
0.807
0.778
0.828
0.831

Table 9. Magnitude of Effect Sizes for Predictors of HPV Vaccination
Effect Size
Statistic

Effect Size
Magnitude

Female Gender

Cramer's V = .47

Large

Higher Perceived Responsibility

R-squared = .07

Medium

Younger age

R-squared = .06

Medium

Having Insurance

Cramer’s V = .11

Small

Hispanic Ethnicity

Cramer's V = .10

Small

White Race

Cramer's V = .09

Small

Smoking

R-squared = .01

Small

Higher Knowledge

R-squared = .01

Small

Sexual Orientation

---

---

Number of lifetime sexual partners

---

---

Frequency of Condom Use

---

---

Predictors of HPV vaccination

Factors unrelated to HPV vaccination
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Table 10. Results of Principal Components Analysis for Decisional Balance
Scale
Factor
Loadings
Pros Scale (α = .84)
Protecting myself from HPV would make me feel good.

.85

I would be protected from getting certain cancers and genital warts.

.81

I would be perceived as more responsible if I were to get
vaccinated.

.64

I would be protecting myself from getting an STD.

.80

I would be less likely to spread HPV.

.81

Cons (α = .80)
I would not fit in with my friends because they have not received
the vaccine.

.75

Receiving the series of three shots would take too much time.

.61

It would be too embarrassing to talk to my parents or doctor about
getting vaccinated.

.79

My partner would not approve of me receiving the vaccine.

.75

My parents would know I was having sex if I got vaccinated.

.80

Note. Bolded items are in the male, but not the female, Decisional Balance
Measure.
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Table 11. Results of Principal Components Analysis for Self-Efficacy Scale
Factor
Loadings
.74
When my significant other does not want me to get the vaccine.
When I think about the possible side effects of the vaccine.
.72
When I anticipate that the shot will be painful.
.74
.74
When my family is against me getting vaccinated.
When I anticipate feeling faint or dizzy when getting the shot.
.81
When it is inconvenient.
.82
When it is too expensive.
.66
Note. Bold items are included in the male, but not the female, Self-Efficacy
Measure
Self-Efficacy (α = 0.87)
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Table 12. Fit indices for Decisional Balance and Self-Efficacy Confirmatory
models
χ2 (df)

GFI

CFI

AASR RMSEA

Decisional balance
Model 1: Null Model
644.9 (45)*
--------Model 2: uncorrelated two
factor model
82.6 (35)*
0.92 0.92 0.057
0.09
Model 3: correlated two factor
model
82.6 (34)*
0.92 0.92 0.057
0.09
Self-Efficacy
Model 1: Null Model
405.3 (21)*
--------Model 2: one factor model
43.4 (14)*
0.93 0.92 0.04
0.11
Note. N = 171, χ2 = chi square, df = degrees of freedom, GFI = goodness of fit,
index, CFI = comparative fit index, AASR =average absolute standardized residual
statistic, *p < .001
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Table 13. Means and Standard Deviations of Raw Scores for Decisional Balance and
Self-Efficacy across the Stages of Change
PC
C
Prep
A/M
Mean

SD

Mean

SD

Mean

SD

Mean

SD

Pros Sum Score

17.84

4.33

19.33

4.12

21.24

3.35

19.91

4.22

Cons Sum Score

9.54

4.30

10.15

4.23

10.41

6.22

9.66

5.06

18.60

6.16

20.75

6.40

23.06

7.07

21.24

5.49

Self-Efficacy Sum
Score

PC = Precontemplation, C = Contemplation, Prep = Preparation, A/M =
Action/Maintenance.
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Table 14. Goodness of Fit Statistics for Invariance Models
Model

χ2(df)

Δ χ2
--

CFI

Δ CFI

NFI

NNFI

RMSEA

Decisional Balance
0.965
-0.949

0.951

0.069

Configural Invariance

118.61 (40)

Pattern Identity Invariance

163.49 (48)

44.88 (8)***

0.949

0.016

0.929

0.940

0.076

Strong Factorial Invariance

328.28 (56)

164.79 (8)***

0.889

0.060

0.869

0.873

0.108

Self-Efficacy
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Configural Invariance

28.10 (10)

--

0.987

--

0.980

0.974

0.068

Pattern Identity Invariance

40.77 (15)

12.67 (5) *

0.982

0.005

0.972

0.976

0.065

Strong Factorial Invariance

65.52 (20)

24.75 (5)***

0.966

0.016

0.953

0.953

0.077

* p < .05, *** p < .001

Figure 1. Stages of Change for HPV Vaccination
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Figure 2. Knowledge Scale Structural Model
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Figure 3. Perceived Responsibility Structural Model
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Figure 4. Male Decisional Balance Confirmatory Model
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Figure 5. Male Self-Efficacy Confirmatory Model
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Figure 6. Stage of Change by Decisional Balance ANOVA results

80
Note. Results are weighted by Stage of Change

Figure 7. Stage of Change by Self-Efficacy ANOVA results
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Note. Results are weighted by Stage of Change

Figure 8. Decisional Balance CFA Model with Standardized Parameter Estimates for the Male and Female Sample.
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Figure 9. Self-Efficacy CFA model with Standardized Parameter Estimates for the
Male and Female Sample.
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APPENDIX A

HPV STUDY QUESTIONNAIRE
Created: January 27 2012, 1:55 PM
Last Modified: February 13 2012, 11:15 AM
Design Theme: Clean
Language: English
Button Options: Custom: Start Survey: "Start Survey!" Submit: "Submit"
Disable Browser “Back” Button: False

College Student Health Study
Page 1 - Heading

INFORMED CONSENT FORM
Title of Research Protocol: Prevention of the Human Papillomavirus (HPV) Among Male and
Female College Students

Page 1 - Heading

You have been asked to take part in a research study described below. If you have questions
at any time, you may discuss them with principal investigator Dr. James Prochaska or coinvestigator Dr. Colleen Redding. They may be reached at 401-874-2830.
Description of the Project: The purpose of this research is to test a survey intended to assess
stage of change progress toward receiving the human papillomavirus (HPV) vaccine in
college-age men and women.
What will be Done: You are one of 800 men and women who will be asked to complete a
survey that asks about human papillomavirus (HPV) vaccination, HPV-related knowledge,
demographics, sexual activity, and attitudes toward the HPV vaccination. To participate, you
must be a student at URI, able to read and speak English, and at least 18 years of age. The
survey is administered online and should take approximately 45 minutes, and you will be
receiving research-credit points towards your grade in this class for your participation.
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Page 1 - Heading

Risks or Discomforts: You might experience some discomfort discussing your sexual
behaviors. If you do not wish to share sexual history information you may skip any or all
questions in the “sexual history section” of the survey. There are no other known risks
associated with participating in this study.
Expected Benefits of the Study: You may not receive any direct benefit from taking part in this
study. Taking part in the study, however, may help others like you in the future. Some people
may find participation in this research informative and personally beneficial.
Confidentiality: Participation in this project is completely confidential and anonymous. Your
information will not be shared with anyone except study personnel working for the Cancer
Prevention Research Center. Survey responses to assessment questions will be stored by the
secure database of the survey company server (Zoomerang). We will not collect or store IP
addresses. Zoomerang make no effort to identify individual responders by IP address and
their privacy practices are reviewed for compliance by TRUSTe. Zoomerang databases are
protected by passwords and database and network firewalls to protect survey information.
After online data collection is complete, the data will be transferred to a secure server at URI
which is firewall protected with restricted access to study personnel through a virtual private
network (VPN). These data will be destroyed within ten years of the collection date.

Page 1 - Heading

Decision to Quit at Any Time: Taking part in this study is entirely voluntary. If you wish, you
may discontinue the survey at any time. You need not give any reasons for discontinuation.
Your decision about whether or not to complete the survey will in no way affect on your
relationship with the Cancer Prevention Research Center, the personnel associated with this
study, or employees of the University of Rhode Island.
Rights and Complaints: If you are not satisfied with the way this study is performed, or if you
have questions about your rights as a research subject, you may discuss your concerns with
Dr. James Prochaska (401-874-2830), anonymously, if you choose. In addition, you may
contact the office of the Vice President of Research, 70 Lower College Road, Suite 2,
University of Rhode Island, Kingston, RI 02882 (401-874-4328).

Page 1 - Question 1 - Yes or No

You have read this Consent Form and currently have no further questions concerning your
participation in this project. You understand that you may ask any additional questions at any
time and that your participation in this project is voluntary. By participating in the project, you
agree that your answers can be used without your signed consent.
By clicking "yes" on this form I am indicating that I understand the information provided and I
agree to participate in this project. If I do not wish to participate, I can click "no" with no
penalty.

 Yes
 No [Screen Out]
Page 2 - Question 2 - Choice - One Answer (Bullets)

How old are you?

 Under 18 [Screen Out]
 18
 19
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20
21
22
23
24
25
26
Over 26 [Screen Out]

Page 3 - Question 3 - Choice - One Answer (Bullets)

Where did you hear abou this survey?






URI class
e-mail
Facebook
Survey Sampling Company

Page 3 - Question 4 - Choice - One Answer (Bullets)

What is your religion? (Please write 'none' if you do not identify with a particular religious
group.)











Catholic
Christian (not Catholic)
Jewish
Muslim
Buddhist
Hindi
Atheist or Agnostic
Don't Know/Not Sure
Other, please specify

Page 3 - Question 5 - Yes or No

Are you Hispanic or Lanino/Latina?

 Yes
 No
Page 3 - Question 6 - Choice - One Answer (Bullets)

What is your race?








White
Black
Asian
Native American/Alaskan Native
Hawaiian/Pacific Islander
Other, please specify
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Page 3 - Question 7 - Choice - One Answer (Bullets)

What year are you in school?








Freshman
Sophomore
Junior
Senior
5th Year Undergraduate
Other

Page 3 - Question 8 - Yes or No

Are you a member of the Greek system (i.e. fraternity/sorority?)

 Yes
 No
Page 3 - Question 9 - Yes or No

Are you a member of a URI sports team?

 Yes
 No
Page 3 - Question 10 - Choice - One Answer (Bullets)

What is your estimated GPA?










< 1.5
1.6 - 2.0
2.1 - 2.5
2.6 - 3.0
3.1 - 3.5
3.6 - 4.0
Don't Know/Not Sure
Other, please specify

Page 3 - Question 11 - Choice - One Answer (Bullets)

Which best describes your current place of residence?







Dormitory/On-campus Housing
Off-campus Apartment/House
Parent's/Legal Guardian's Home
Other Family Member's Home
Other
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Page 3 - Question 12 - Open Ended - One Line

What is the zip code in which your primary parent or guardian resides?

Page 3 - Question 13 - Choice - One Answer (Bullets)

Do you have health insurance?

 Yes
 No
 Don't Know
Page 4 - Heading

The next series of questions will ask you about HPV. HPV is also known as the human
papillomavirus. It is a common sexually transmitted disease. There is a vaccine that can
protect you against the most common types of HPV. This vaccine was first available only for
girls and women but is now also available for boys and young men ages 9 - 26 year-old.

Page 4 - Question 14 - Choice - One Answer (Bullets)

Have you heard of the human papillomavirus (HPV) before today?

 Yes
 No [Skip to 8]
Page 5 - Question 15 - Open Ended - Comments Box

Is so, what comes to mind when you think of HPV?

Page 6 - Question 16 - Choice - One Answer (Bullets)

Did you know that the HPV vaccine was approved for use among men before today?

 Yes
 No [Skip to 8]
Page 7 - Question 17 - Choice - Multiple Answers (Bullets)

How did you find out that the HPV vaccine was approved for use among men (select as many
answer options as applicable)






Parent or Other Family Member
Friend
Health Class
College Class
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Doctor or Health Care Provider
Advertisement/Media
News
Other, please specify

Page 8 - Question 18 - Choice - One Answer (Bullets)

Have you completed the HPV vaccine series (3 shots)?

 Yes [Skip to 11]
 No
Page 9 - Question 19 - Yes or No

Have you recieved any of the HPV vaccine shots?

 Yes
 No [Skip to 19]
Page 10 - Question 20 - Choice - One Answer (Bullets)

How many of the HPV vaccine shots have you recieved?

 1
 2
[Skip Unconditionally to 12]
Page 11 - Question 21 - Yes or No

Did you recieve the last of your three HPV vaccine shots within the past year?

 Yes [Skip to 13]
 No [Skip to 15]
Page 12 - Question 22 - Yes or No

Did you recieve your last HPV vaccine shot within the past year?

 Yes [Skip to 14]
 No [Skip to 16]
Page 13 - Question 23 - Choice - One Answer (Bullets)

In what month did you get the last of your three HPV vaccine shots?






January
February
March
April
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May
June
July
August
September
October
November
December

[Skip Unconditionally to 21]
Page 14 - Question 24 - Choice - One Answer (Bullets)

In what month did you get your last HPV vaccine shot?














January
February
March
April
May
June
July
August
September
October
November
December

[Skip Unconditionally to 17]
Page 15 - Question 25 - Choice - One Answer (Bullets)

How old were you when you recieved the last of your three HPV vaccine shots?

















< 12
12
13
14
15
16
17
18
19
20
21
22
23
24
25
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[Skip Unconditionally to 21]
Page 16 - Question 26 - Choice - One Answer (Bullets)

How old were you when you recieved your last HPV vaccine shot?

















< 12
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Page 17 - Question 27 - Choice - One Answer (Bullets)

Are you intending to complete the HPV vaccination series?

 No, I do not plan to complete the HPV vaccination series.
 Yes, I plan to complete the HPV vaccination series but NOT within the next 6 months.


[Skip to 21]
Yes, I plan to complete the HPV vaccination series within the next 6 months. [Skip to
21]

Page 18 - Question 28 - Open Ended - One Line

Why are you NOT planning on finishing the HPV vaccination series?

[Skip Unconditionally to 21]
Page 19 - Question 29 - Choice - One Answer (Bullets)

Are you intending to start the HPV vaccination series?

 No, I do not plan on starting the HPV vaccination series in the next 6 months.
 Yes, I plan on starting the HPV vaccination series within the next 6 months. [Skip to
23]

 Yes, I plan on starting the HPV vaccination series within the next 30 days. [Skip to 23]
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Page 20 - Question 30 - Open Ended - One Line

Why are you not planning to start the HPV vaccination series?

[Skip Unconditionally to 23]
Page 21 - Question 31 - Choice - One Answer (Bullets)

Who initiated/recommended the HPV vaccination series?







Mother
Father
Yourself
Health Care Provider/Doctor
Other, please specify

Page 22 - Question 32 - Choice - One Answer (Bullets)

Were you aware of what you were being vaccinated for when you received the HPV
vaccination series?

 Not at all aware
 Somewhat aware
 Completely aware
Page 23 - Question 33 - Choice - One Answer (Bullets)

What gender are you?

 Male
 Female [Skip to 28]
Page 24 - Heading

Instructions: The next series of questions will ask you about your personal/sexual history.

Page 24 - Question 34 - Choice - Multiple Answers (Bullets)

Have you ever had vaginal, anal, or oral sex with a woman? PLEASE CHECK ALL THAT
APPLY






Vaginal Sex [Skip to 25]
Anal Sex [Skip to 25]
Oral Sex [Skip to 26]
None of the Above [Skip to 26]
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Page 25 - Question 35 - Open Ended - One Line

How old were you the first time you had vaginal or anal sex with a woman?

Page 25 - Question 36 - Open Ended - One Line

Approximately how many women have you had vaginal or anal sex with?

Page 25 - Question 37 - Choice - One Answer (Bullets)

How often do you use condoms when having vaginal or anal sex with women?







Never
Rarely
Sometimes
Often
Always

Page 26 - Question 38 - Choice - Multiple Answers (Bullets)

Have you ever had anal or oral sex with a man? PLEASE CHECK ALL THAT APPLY

 Anal Sex [Skip to 27]
 Oral Sex [Skip to 27]
 None of the Above [Skip to 32]
Page 27 - Question 39 - Open Ended - One Line

How old were you the first time you had anal sex with man?

Page 27 - Question 40 - Open Ended - One Line

Approximately how many men have you had anal sex with?

Page 27 - Question 41 - Choice - One Answer (Bullets)

How often do you use condoms when having anal sex with men?







Never
Rarely
Sometimes
Often
Always

[Skip Unconditionally to 32]
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Page 28 - Heading

The next series of questions will ask you about your personal/sexual history.

Page 28 - Question 42 - Choice - Multiple Answers (Bullets)

Have you ever had vaginal, anal, or oral sex with a man? PLEASE CHECK ALL THAT
APPLY.






Vaginal Sex [Skip to 29]
Anal Sex [Skip to 29]
Oral Sex [Skip to 30]
None of the above [Skip to 30]

Page 29 - Question 43 - Open Ended - One Line

How old were you the first time you had vaginal or anal sex with a man?

Page 29 - Question 44 - Open Ended - One Line

Approximately how many men have you had vaginal or anal sex with in your lifetime?

Page 29 - Question 45 - Choice - One Answer (Bullets)

How often do you use condoms when having vaginal or anal sex with men?







Never
Rarely
Sometimes
Often
Always

Page 30 - Question 46 - Choice - One Answer (Bullets)

Have you ever had any sexual contact with a woman?

 Yes
 No [Skip to 32]
Page 31 - Question 47 - Open Ended - One Line

Approximately how many women have you had sexual contact with in your lifetime?

Page 32 - Question 48 - Choice - One Answer (Bullets)

What is your sexual orientation?

 Heterosexual
 Homosexual
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 Bisexual
 Other, please specify

Page 33 - Question 49 - Yes or No

Have you ever been diagnosed with HPV?

 Yes
 No
Page 33 - Question 50 - Yes or No

Have you ever had/been diagnosed with genital warts?

 Yes
 No
Page 33 - Question 51 - Yes or No

Do you know anyone who has been diagnosed with HPV?

 Yes
 No
Page 33 - Question 52 - Choice - One Answer (Bullets)

How often do you currently smoke or use other tobacco products?







Daily
Weekly
Monthly
Less than Monthly
Not at All

Page 34 - Heading

Instructions: Next are some questions related to your knowledge about the human
papillomavirus (HPV). If you are not sure of the answer to a questions please mark 'Don't
Know.'

Page 34 - Question 53 - Choice - One Answer (Bullets)

A person may be infected with HPV and not know it.

 True
 False
 Don't Know
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Page 34 - Question 54 - Choice - One Answer (Bullets)

HPV does not cause cervical cancer.

 True
 False
 Don't Know
Page 34 - Question 55 - Choice - One Answer (Bullets)

Vaccination can help prevent HPV infection in men and women.

 True
 False
 Don't Know
Page 34 - Question 56 - Choice - One Answer (Bullets)

HPV can lead to cancers of the anus, vagina, penis, throat, and mouth

 True
 False
 Don't Know
Page 34 - Question 57 - Choice - One Answer (Bullets)

Only women are at risk for health problems related to HPV

 True
 False
 Don't Know
Page 34 - Question 58 - Choice - One Answer (Bullets)

HPV can only be spread through sexual intercourse

 True
 False
 Don't Know
Page 34 - Question 59 - Choice - One Answer (Bullets)

HPV is transmitted or spread via genital contact.

 True
 False
 Don't Know
Page 34 - Question 60 - Choice - One Answer (Bullets)

Men are not routinely tested for HPV

 True
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 False
 Don't Know
Page 34 - Question 61 - Choice - One Answer (Bullets)

Genital warts are unrelated to HPV.

 True
 False
 Don't Know
Page 34 - Question 62 - Choice - One Answer (Bullets)

For most people an HPV infection goes away on its own

 True
 False
 Don't Know
Page 34 - Question 63 - Choice - One Answer (Bullets)

A person cannot transmit HPV if he/she does not have symptoms.

 True
 False
 Don't Know
Page 34 - Question 64 - Choice - One Answer (Bullets)

Most persons with HPV have no visible signs or symptoms.

 True
 False
 Don't Know
Page 34 - Question 65 - Choice - One Answer (Bullets)

Condoms fully prevent against HPV transmission.

 True
 False
 Don't Know
Page 34 - Question 66 - Choice - One Answer (Bullets)

HPV testing is part of routine STD testing for women.

 True
 False
 Don't Know
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Page 34 - Question 67 - Choice - One Answer (Bullets)

People who already have HPV cannot benefit from getting the vaccine.

 True
 False
 Don't Know
Page 34 - Question 68 - Choice - One Answer (Bullets)

If you started the HPV vaccination series, and missed a shot, you have to re-start the series
from the beginning.

 True
 False
 Don't Know
Page 34 - Question 69 - Choice - One Answer (Bullets)

HPV vaccination is covered by private insurance for women but not men.

 True
 False
 Don't Know
Page 35 - Heading

Please read before completing the next questions.......
The human papillomavirus (HPV) is a sexually transmitted disease. There are more than 40
types of HPV that are passed through sexual contact. These types can infect the genital areas
of men and women, including the skin on and around the genitals or anus. They can also
infect the mouth and throat. Most people who get HPV (of any type) never develop any
symptoms or health problems, but some types of HPV can cause genital warts. Other types
can cause cervical, vaginal, penile, anal, or head and neck cancers. The 3-shot HPV vaccine
series is administered over a 6-month period. It costs between $300 and $400 and is covered
by insurance for women but not for men.

Page 36 - Heading

Instructions: Next are some thoughts and feelings people may have about HPV vaccination.
Please tell us how important each one is to you in your decision of whether or not you get the
HPV vaccination series.
If an answer does not apply to you please mark “Not important at all.” If you have already
received the vaccine, please think about how important each one was in your decision to get
the HPV vaccination series.

Page 36 - Question 70 - Choice - One Answer (Bullets)

The vaccination would cost me too much money.

 Not Important At All
 A Little Important
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 Important
 Very Important
 Extremely Important
Page 36 - Question 71 - Choice - One Answer (Bullets)

Getting the vaccine would make me uncomfortable because I hate shots.







Not Important At All
A Little Important
Important
Very Important
Extremely Important

Page 36 - Question 72 - Choice - One Answer (Bullets)

Getting the vaccine could help keep HPV from spreading.







Not Important at All
A Little Important
Important
Very Important
Extremely Important

Page 36 - Question 73 - Choice - One Answer (Bullets)

Getting the vaccine would reduce the risk of future partners developing genital warts or
cancer.







Not Important at All
A Little Important
Important
Very Important
Extremely Important

Page 36 - Question 74 - Choice - One Answer (Bullets)

Protecting myself from HPV would make me feel good.







Not Important at All
A Little Important
Important
Very Important
Extremely Important

Page 36 - Question 75 - Choice - One Answer (Bullets)

Having the vaccine would allow future partners to feel more comfortable having sex with me.

 Not Important at All
 A Little Important
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 Important
 Very Important
 Extremely Important
Page 36 - Question 76 - Choice - One Answer (Bullets)

I would be protected from getting certain cancers and genital warts.







Not Important at All
A Little Important
Important
Very Important
Extremely Important

Page 36 - Question 77 - Choice - One Answer (Bullets)

The vaccination could cause side-effects and unknown long-term risks.







Not Important at All
A Little Important
Important
Very Important
Extremely Important

Page 36 - Question 78 - Choice - One Answer (Bullets)

I would be perceived as more responsible if I were to get vaccinated.







Not Important at All
A Little Important
Important
Very Important
Extremely Important

Page 36 - Question 79 - Choice - One Answer (Bullets)

I would not fit in with my friends because they have not received the vaccine.







Not Important at All
A Little Important
Important
Very Important
Extremely Important

Page 37 - Question 80 - Choice - One Answer (Bullets)

I would cause shame to my family/religion.

 Not Important at All
 A Little Important
 Important
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 Very Important
 Extremely Important
Page 37 - Question 81 - Choice - One Answer (Bullets)

Receiving the series of three shots would take too much time.







Not Important at All
A Little Important
Important
Very Important
Extremely Important

Page 37 - Question 82 - Choice - One Answer (Bullets)

My doctor would approve of me getting the vaccination series.







Not Important at All
A Little Important
Important
Very Important
Extremely Important

Page 37 - Question 83 - Choice - One Answer (Bullets)

People close to me would be happy with me if I received the vaccination series.







Not Important at All
A Little Important
Important
Very Important
Extremely Important

Page 37 - Question 84 - Choice - One Answer (Bullets)

I would be protecting myself from getting an STD.







Not Important at All
A Little Important
Important
Very Important
Extremely Important

Page 37 - Question 85 - Choice - One Answer (Bullets)

It would be too embarrassing to talk to my parents or doctor about getting vaccinated.






Not Important at All
A Little Important
Important
Very Important
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 Extremely Important
Page 37 - Question 86 - Choice - One Answer (Bullets)

My partner would not approve of me receiving the vaccine.







Not Important at All
A Little Important
Important
Very Important
Extremely Important

Page 37 - Question 87 - Choice - One Answer (Bullets)

I would be a role model for my peers if I got vaccinated.







Not Important at All
A Little Important
Important
Very Important
Extremely Important

Page 37 - Question 88 - Choice - One Answer (Bullets)

I would be less likely to spread HPV.







Not Important at All
A Little Important
Important
Very Important
Extremely Important

Page 37 - Question 89 - Choice - One Answer (Bullets)

My parents would think/know I was having sex if I got vaccinated.







Not Important at All
A Little Important
Important
Very Important
Extremely Important

Page 37 - Question 90 - Choice - One Answer (Bullets)

Getting vaccinated would reduce my current/future partner(s) fear of contracting HPV.







Not Important at All
A Little Important
Important
Very Important
Extremely Important
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Page 37 - Question 91 - Choice - One Answer (Bullets)

People would think I was having risky sex if I got vaccinated.







Not Important at All
A Little Important
Important
Very Important
Extremely Important

Page 38 - Heading

Instructions: In the following kinds of situations it may be harder to make a decision to get the
HPV vaccination and to stay on schedule when getting the shots. Please tell us how confident
you are you would get the vaccine in the following situations.
HOW CONFIDENT ARE YOU THAT YOU WOULD GET THE VACCINE WHEN.......

Page 38 - Question 92 - Choice - One Answer (Bullets)

When I don’t know how others will respond to my getting the vaccine.







Not at All Confident
A Little Confident
Confident
Very Confident
Extremely Confident

Page 38 - Question 93 - Choice - One Answer (Bullets)

When my significant other does not want me to get the vaccine.







Not at All Confident
A Little Confident
Confident
Very Confident
Extremely Confident

Page 38 - Question 94 - Choice - One Answer (Bullets)

When my friends are unsupportive of me getting the HPV vaccine.







Not at All Confident
A Little Confident
Confident
Very Confident
Extremely Confident
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Page 38 - Question 95 - Choice - One Answer (Bullets)

When it seems too difficult to fit into my schedule.







Not at All Confident
A Little Confident
Confident
Very Confident
Extremely Confident

Page 38 - Question 96 - Choice - One Answer (Bullets)

When I think about the possible side effects of the vaccine.







Not at All Confident
A Little Confident
Confident
Very Confident
Extremely Confident

Page 38 - Question 97 - Choice - One Answer (Bullets)

When I have to go somewhere unfamiliar to get the shot.







Not at All Confident
A Little Confident
Confident
Very Confident
Extremely Confident

Page 38 - Question 98 - Choice - One Answer (Bullets)

When I am stressed.







Not at All Confident
A Little Confident
Confident
Very Confident
Extremely Confident

Page 38 - Question 99 - Choice - One Answer (Bullets)

When I anticipate that the shot will be painful.







Not at All Confident
A Little Confident
Confident
Very Confident
Extremely Confident
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Page 38 - Question 100 - Choice - One Answer (Bullets)

When my family is against me getting vaccinated.







Not at All Confident
A Little Confident
Confident
Very Confident
Extremely Confident

Page 38 - Question 101 - Choice - One Answer (Bullets)

When I anticipate feeling faint or dizzy when getting the shot.







Not at All Confident
A Little Confident
Confident
Very Confident
Extremely Confident

Page 38 - Question 102 - Choice - One Answer (Bullets)

When it is inconvenient.







Not at All Confident
A Little Confident
Confident
Very Confident
Extremely Confident

Page 38 - Question 103 - Choice - One Answer (Bullets)

When it is too expensive.







Not at All Confident
A Little Confident
Confident
Very Confident
Extremely Confident

Page 38 - Question 104 - Choice - One Answer (Bullets)

I know my partner(s) has already been vaccinated







Not at All Confident
A Little Confident
Confident
Very Confident
Extremely Confident
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Page 39 - Heading

The following statements describe different beliefs people may have about vaccines in
general. They do not necessarily reflect the beliefs of the researchers or the Centers for
Disease Control (CDC). Please rate how much you agree with each statement.

Page 39 - Question 105 - Choice - One Answer (Bullets)

If others get vaccinated I don't need to







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 39 - Question 106 - Choice - One Answer (Bullets)

Vaccines cause autism and other disorders







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 39 - Question 107 - Choice - One Answer (Bullets)

A vaccine may cause the disease it is intended to prevent







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 39 - Question 108 - Choice - One Answer (Bullets)

Vaccines protect the public health







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 39 - Question 109 - Choice - One Answer (Bullets)

Healthcare organizations only recommend vaccines that are safe and effective

 Completely Disagree
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Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 39 - Question 110 - Choice - One Answer (Bullets)

Vaccines cause more harm than good







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 39 - Question 111 - Choice - One Answer (Bullets)

Getting too many vaccines can overwhelm the immune system causing adverse reactions or
serious illness







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 39 - Question 112 - Choice - One Answer (Bullets)

Vaccines are a conspiracy so drug companies can make money







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 39 - Question 113 - Choice - One Answer (Bullets)

If my doctor recommends a vaccine I should probably get it







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 39 - Question 114 - Choice - One Answer (Bullets)

Vaccines contain dangerous preservatives (life mercury) that can harm the body

 Completely Disagree
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Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 39 - Question 115 - Choice - One Answer (Bullets)

The news/media exaggerates the risks associated with vaccines







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 39 - Question 116 - Choice - One Answer (Bullets)

The benefits of vaccination outweight the risks







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 40 - Heading

The following statements describe different beliefs people may have about the HPV vaccine.
They do not necessarily reflect the beliefs of the researchers or the Centers for Disease
Control (CDC). Please rate how much you agree with the following statements.

Page 40 - Question 117 - Choice - One Answer (Bullets)

There is not enough research on the safety of the HPV vaccine







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 40 - Question 118 - Choice - One Answer (Bullets)

The HPV vaccine shots are very painful







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree
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Page 40 - Question 119 - Choice - One Answer (Bullets)

The HPV vaccine may cause lasting health problems







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 40 - Question 120 - Choice - One Answer (Bullets)

The HPV vaccine has not been available long enough for the medical community to know the
long-term risks







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 40 - Question 121 - Choice - One Answer (Bullets)

The HPV vaccine may cause short-term problems like fever or discomfort







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 40 - Question 122 - Choice - One Answer (Bullets)

The HPV vaccine could cause dangerous side effects







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 40 - Question 123 - Choice - One Answer (Bullets)

The HPV vaccine can cause serious health problems or even death







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree
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Page 40 - Question 124 - Choice - One Answer (Bullets)

The HPV vaccine is just a way for drug companies to make money.







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 40 - Question 125 - Choice - One Answer (Bullets)

The HPV vaccine could make me infertile







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 40 - Question 126 - Choice - One Answer (Bullets)

People in monogamous relationships don't need the HPV vaccine







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 40 - Question 127 - Choice - One Answer (Bullets)

Getting the HPV vaccine sends the message that pre-marital sex is acceptable







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 40 - Question 128 - Choice - One Answer (Bullets)

I think the HPV vaccine is unsafe







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree
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Page 40 - Question 129 - Choice - One Answer (Bullets)

The HPV can cause mental retardation in children







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 41 - Question 130 - Choice - One Answer (Bullets)

Imagine that you got genital warts and the HPV vaccine could have prevented it. How much
would you regret that you did NOT get the HPV vaccine? (If you have already received the
vaccine, please answer this question as if you had not recieved the HPV vaccination series.)






Not At All
A Little
A Moderate Amount
Alot

Page 41 - Question 131 - Choice - One Answer (Bullets)

Imagine that you got an HPV infection that could lead to oral, anal, or genital cancer and the
HPV vaccine could have prevented it. How much would you regret that you did NOT get the
HPV vaccine? (If you have already received the vaccine, please answer this question as if you
had not recieved the HPV vaccination series.)






Not At All
A Little
A Moderate Amount
Alot

Page 41 - Question 132 - Choice - One Answer (Bullets)

Imagine that you are diagnosed with a cancer that was likely caused by and HPV infection and
the HPV vaccine could have prevented it. How much would you regret that you did NOT get
the HPV vaccine? (If you have already received the vaccine, please answer this question as if
you had not recieved the HPV vaccination series.)






Not At All
A Little
A Moderate Amount
Alot

Page 42 - Heading

The following statements describe different beliefs people may have about HPV vaccination.
Please rate how much you agree with the following statements.
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Page 42 - Question 133 - Choice - One Answer (Bullets)

Anyone engaging in sexual activity (male or female) should get the HPV vaccine







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 42 - Question 134 - Choice - One Answer (Bullets)

If women get the HPV vaccine men don't need to







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 42 - Question 135 - Choice - One Answer (Bullets)

Men AND women should receive the HPV vaccine







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 42 - Question 136 - Choice - One Answer (Bullets)

Insurance companies should pay for the HPV vaccine for MEN







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 42 - Question 137 - Choice - One Answer (Bullets)

A womam should tell her partners if they knows/suspects she has HPV







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree
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Page 42 - Question 138 - Choice - One Answer (Bullets)

A man should tell his partner if he knows/suspects he has HPV







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 42 - Question 139 - Choice - One Answer (Bullets)

Insurance companies should pay for the HPV vaccine for WOMEN







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 43 - Heading

The following set of questions refer to your percieved risk for contracting HPV or experiencing
an HPV-related health problem.

Page 43 - Question 140 - Choice - One Answer (Bullets)

I am not at risk for developing an HPV-related cancer







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 43 - Question 141 - Choice - One Answer (Bullets)

I am not at risk for contracting HPV







Completely Disagree
Somewhat Disagree
Neither Agree nor Disagree
Somewhat Agree
Completely Agree

Page 43 - Question 142 - Choice - One Answer (Bullets)

I am not at risk for developing genital warts.

 Completely Disagree
 Somewhat Disagree
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 Neither Agree nor Disagree
 Somewhat Agree
 Completely Agree
Page 43 - Question 143 - Choice - One Answer (Bullets)

Relative to the average college student, my risk of contracting HPV is:







Much Lower
Slightly Lower
About the Same
Slightly Higher
Much Higher

Page 44 - Heading

The following set of questions refers to your perceptions of HPV prevalence on campus. Most
people do not know these answers, but we are interested in your best answer.

Page 44 - Question 144 - Choice - One Answer (Bullets)

What percentage of FEMALE students at URI do you think have received the HPV vaccine?











0% to 10%
10% - 20%
20% - 30%
30% - 40%
50% - 60%
60% - 70%
70% - 80%
80% - 90%
90% - 100%

Page 44 - Question 145 - Choice - One Answer (Bullets)

What percentage of MALE students at URI do you think have received the HPV vaccine?











0% to 10%
10% - 20%
20% - 30%
30% - 40%
50% - 60%
60% - 70%
70% - 80%
80% - 90%
90% - 100%
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Page 44 - Question 146 - Choice - One Answer (Bullets)

What percentage of FEMALE students at URI do you think has had an HPV infection? (Please
estimate prevalence for all women, not just those who were diagnosed).











0% to 10%
10% - 20%
20% - 30%
30% - 40%
50% - 60%
60% - 70%
70% - 80%
80% - 90%
90% - 100%

Page 44 - Question 147 - Choice - One Answer (Bullets)

What percentage of MALE students at URI do you think has had an HPV infection? (Please
estimate prevalence for all men, not just those who were diagnosed).











0% to 10%
10% - 20%
20% - 30%
30% - 40%
50% - 60%
60% - 70%
70% - 80%
80% - 90%
90% - 100%

Page 44 - Question 148 - Choice - One Answer (Bullets)

What percentage of FEMALE students at URI do you think has had gential warts?











0% to 10%
10% - 20%
20% - 30%
30% - 40%
50% - 60%
60% - 70%
70% - 80%
80% - 90%
90% - 100%

Page 44 - Question 149 - Choice - One Answer (Bullets)

What percentage of MALE students at URI do you think has had gential warts?






0% to 10%
10% - 20%
20% - 30%
30% - 40%
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50% - 60%
60% - 70%
70% - 80%
80% - 90%
90% - 100%

Thank You Page

THANK YOU FOR PARTICIPATING IN OUR SURVEY.<br /><br />IF YOU ARE
COMPLETING THIS SURVEY AS PART OF A CLASS PRINT THIS PAGE AND BRING IT
TO YOUR PROFESSOR TO RECEIVE EXTRA CREDIT.<br /><br />This screen will serve as
verification that you completed the college student health survey: IRB approval # HU1011107<br /><br />

Screen Out Page

We are sorry, but based on your responses you are not eligible to participate in this study.
Thank you for your time. If you would like more information on the study or your eligibility feel
free to contact the principal investigator Dr. James Prochaska at 401-874-2830.
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Survey Closed Page

Standard
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